The management of anxiety:

Counseling and pharmacotherapy
Changing the patient's
perspective
In the management of anxiety, the
negative feelings the patient has about
himself and his behavior may often be
altered in a positive manner by discussion, counseling and reassurance.
Changing the patient's perspective is
often the first significant step toward
helping him to learn more appropriate,
less anxious ways of living. The physician recognizes that the patient has certain positive qualities and he utilizes this
"healthy core" to effect constructive
change in outlook and life-style. When

excessive anxiety is reduced through
such a psychotherapeutic approach,
there is no need for adjunctive psychotropic medication.

The patient
and his milieu
The physician
may also take steps
to identify and mobilize constructive
factors in the patient's••
over-all environment- a motherly
neighbor, a dependable friend, a community club- that could furnish favorable experiences and thereby help
reduce his anxiety. A change in environment to remove undesirable influences
or modifications in the patient's work,
personal associations and recreational
activities may be indicated.

Short-term psychotherapy
A great deal may be accomplished
for the anxious patient in regular therapeutic sessions lasting as little as 10 to
15 minutes. These may be scheduled for
one to four times monthly over a specified period, depending on the level of
the patient's anxiety and the problems
involved. Many interested physicians
have gained increasing skill in this area
through postgraduate training and
experience.

agent can help foster
the necessary rapport and communication between physician and patient. The drug chosen should have a
wide margin of safety and be relatively
free of undesirable side effects. It should
be compatible with other agents required
in the patient's total medical regimen.
When the patient's anxiety has been
reduced to manageable levels, pharmacotherapy should be terminated.

when dependable antianxiety
results are the criteria ...
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The adjunctive role of
pharmacotherapy
When counseling and other nonpharmacologic measures do not prove
sufficiently effective, pharmacotherapy
can provide a valuable adjunct to other
measures. An effective antianxiety
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Broad clinical usefulness in
emotional and somatic disorders
Librium (chlordiazepoxide HCl) is indicated for
the relief of clinically significant anxiety and tension,
and as an adjunct in various disease states in which
anxiety and tension are manifested. It is recognized
as one of the safest of the available antianxiety agents
and is given concomitantly with specific primary
medications where indicated. While drowsiness,
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severe reactions. Before prescribing, consult complete product information.
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Introduction
This issue of the MCV /Q is a continuation of
the first issue of this year, which was devoted to
the subject of Immunology and the Rheumatic
Diseases. Many of the papers presented at the 45th
Annual McGuire Lecture Series were published in
the first issue and this will complete those papers
which were submitted for publication. In addition
to subjects in the fields of juvenile rheumatoid arthritis, ankylosing spondylitis, and infectious arthritis,
papers covering immune complex reactions in SLE
as well as delayed hypersensitivity are included. Because of recent advances in the study of histocompatibility antigens (W-27) in patients with connective
tissue diseases, this subject is also discussed in this
issue.
ROBERT IRBY, M .D.

Professor of Medicine
Department of Medicine
Medical College of Virginia
Virginia Commonwealth University
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Viruses and the Connective Tissue Diseases*
MORRIS ZIFF, M.D ., Ph.D.
Rheumatic Diseases Unit, Department of Internal Medicine,
University of Texas Southwestern Medical School, Dallas

A number of observations in the last few years
have attracted attention to the possibility of viral
infection in systemic lupus erythematosus ( SLE).
One of these is the occurrence of interwoven tubular
structures, usually in the endothelial cells of the
kidney but also in the lymphocytes and in fibroblasts
when SLE skin fibroblasts are cultured. These tubular structures have resembled viruses (they were
thought by thei~ discoverers to be myxo- or paramyxoviruses), but it has been argued ( 1) that
they are not viruses because of their size and appearance and because they have been produced in
tissue cultures from subjects who do not have SLE;
they occur in many other conditions which are not
related to SLE. These tubular structures do not
occur, however, in rheumatoid arthritis (RA). The
conclusion, at this point, would seem to be that
they are not viruses. Nevertheless, from their randomness and their odd app,earance, it seems likely
that we may be seeing the effects of a virus, perhaps a very common ¥irus, on the endoplasmic
reticulum of the cell.
There has been a group of papers in which the
point has been made (2, 3, 4) that the titers of a
number of viral antibodies (usually myxo- and paramyxoviruses) am somewhat elevated in patients
with SLE. It has been argued that this simply
represents the overall hyper-y-globulinemia of SLE,
although we have not noted the relationship with
y-globulin levels. It should be pointed out that there
has been no outstanding elevation of any particular
viral antibody titer. The antibody titer to measles,
an RNA virus, has been consistently elevated to a
significant degree. This may mean that antibody to
this virus cross-reacts well with an unidentified RN A
virus which is actually involved.

* Presented by Dr. Ziff at the 45th Annual McGuire
Lecture Series, November 9, 19'73, at the Medical College
of Virginia, Richmond.
MCV QUARTERLY 10(2): 57-60, 1974

Cellular Immunity in SLE. Hahn and coworkers ( 5) have reviewed the evidence for reduced delayed hypersensitivity in SLE. About half
of investigators have noted decreased skin test reactions in this disease. Patients with SLE also tend
to develop lymphomas somewhat more commonly
than expected. Presumably these patients do not
have adequate immunologic surveillance for rejection of lymphomas on the basis of diminished cellular immunity.
Regarding cellular immunity, it is known that
thymus-derived lymphocytes undergo blastic transformation and produce lymphokines. When the T
cell has been stimulated, it can also subserve the
antigen to stimulate B lymphocytes (bone marrowderived) to produce antibody.
With regard to the possible role of a virus in
SLE and the fact that depressed cellular immunity
seems to be present, it is fairly well accepted that
virus infections, in general, decrease delayed hypersensitivity as measured by skin tests and by the
response of the circulating T cells of the infected
patient to mitogens like PHA and concanavalin.
Also, if one adds a virus like rubella to lymphocyte
cultures, the capacity of the T cells in that culture
to undergo a response to mitogenic agents is diminished.
As is well known, the New Zealand Black
(NZB) mouse, particularly its F 1 hybrid, is an
excellent model for SLE. The NZB F 1 hybrid mouse
has also been shown to have decreased cellular
immunity ( 6). It has a decreased capacity to induce graft-versus-host disease in a recipient mouse
strain. There is also a decreased responsiveness to
mitogenic agents and a high incidence of lymphomas.
For unexplained reasons, T cells in man form
rosettes with sheep red blood cells. These rosettes
represent a measure of the T cells circulating in the
blood. Wybran and Fudenberg (7), using this
57
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method, found that patients with viral infections
have reduced numbers of circulating T lymphocytes.
In our laboratory, Drs. Hurd and Giuliano have
observed decreased numbers of spontaneous rosetteforming cells in patients with SLE suggesting decreased cellular immunity. This could be a result of
coating with an immunosuppressive globulin or a
true deficiency of T cells.
Autoantibody Formation. It should be pointed
out that in SLE, we are concerned not as much with
T cell function as with the results of B cell activity
since these cells produce autoantibodies such as antiDNA, both double- and single-stranded, antinuclear
antibody, anti-RNA, both double- and singlestranded, as well as other types of autoantibodies.
Are such autoantibodies found in virus infections?
Two conditions stand out-one, infectious mononucleosis, an EB virus infection, and the other,
cytomegalovirus infection. In these conditions, we
see antinuclear antibody, rheumatoid factor, mixed
cryoglobulins, Coombs autoantibodies, and so forth.
The NZB mice are infected with murine leukemia viruses. This strain, unlike other strains, does
not develop tolerance to the murine leukemia viruses
and eventually develops antibodies to these viruses.
These form immune complexes which circulate in
the blood and in time the mice develop proteinuria.
The immune complexes eventually deposit in the
basement membrane of the kidney. If NZB F 1
hybrids are injected with nonleukemogenic viruses
such as LCM, which is an RNA virus, or with
polyoma, which is a DNA virus, antinuclear antibody is enhanced, the glomerulonephritis is aggravated and the mortality rate goes up ( 8). These
viruses, it appears, exert an adjuvant effect in stimulating autoantibody formation. Nucleic acids are
known to have adjuvant effects. Weight for weight,
the RNA of the tubercle bacillus is as effective an
adjuvant as the tubercle bacillus itself (9). Powell
and Steinberg (10) have examined the adjuvant
effects in the NZB-NZW mouse of poly I-poly C,
a synthetic double-stranded RNA, and have found
an increase in antibody, not only to double-stranded
RNA, but also an increase to DNA. Cone and
Johnson (11) have shown that poly A-poly U increased the antibody response against sheep red
blood cells. One may speculate from these kinds
of results that the viral nucleic acids may also have
an adjuvant effect on both antibody and autoantibody formation .
It appears likely that if a virus were to be the

cause of SLE, it would be so by affecting T lymphocyte
function. In our laboratory ( 12), we have demonstrated that T cells produce a relatively low molecular weight factor, which has a stimulatory effect on
antibody formation by B cells. Fialkow, Gilchrist
and Allison ( 13) have shown that T cell stimulation
can lead to autoantibody formation. F 1 hybrid mice
injected with parental cells undergo a graft-versushost reaction in which the donor T cells proliferate.
These mice develop antinuclear antibody after each
injection of T cells, presumably because of the
elaboration of a helper factor by the proliferating T
cells.
There is also evidence that a suppressor population of T cells exists which presumably inhibits
autoantibody formation. The first evidence for suppressor T cells came from our laboratory ( 14) in
a study of the effect of antilymphocyte globulin on
the immune response of rabbits. When rats were
treated with this agent, the antibody response to
keyhole limpet hemocyanin was increased instead
of reduced. This result has been interpreted by
others (15) to indicate that there is a type of T
cell whose function is to suppress the antibody
response. Subsequently, Baker and co-workers ( 16)
showed that there was an increased response to
pneumococcal polysaccharide in mice upon treatment with antithymocyte serum.
Recently, Steinberg and co-workers ( 17)
showed that neonatal thymectomy of NZB mice
accelerated the formation of anti-DNA antibodies
and that this change could be reversed by grafting
these mice with one-week old thymuses, but not
with ten-week old thymuses. Suppressor T cells
presumably are lost in the NZB F 1 hybrid at an
early age. This seems to be the cause of the aggravated form of the disease observed in thymectomized
animals.
It is well established that autoantibodies develop
in the aged ( 18). Phytohemagglutinin responsiveness, which is a measure of T cell function, also decreases. These changes may reflect a loss of suppressor T cells with age in man. When Teague and Friou
( 19) administered syngenic thymocytes from young
mice to older mice who were producing antinuclear
antibodies, these antibodies disappeared, suggesting
that suppressor T cell function had been restored.
The explanation for these phenomena, most clearly
enunciated by ·Allison ( 20), is that we are dealing
with a particular type of tolerance in the normal
state which does not permit autoantibodies to form.
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This tolerance resides in the T cell, as originally suggested by Weigle (21). The B cells which produce
antoantibody are not tolerant and when they are
stimulated by helper substance from helper T cells
or freed from the suppressive action of suppressor
T cells, they become free to synthesize autoantibody
in the presence of autoantigen. In speculating about
the role of a virus in autoimmune phenomena, one
might suppose that an infected individual would have
T cells sensitized to the causative virus, whatever
virus that might be. This virus could then stimulate these sensitized T cells to produce a helper
substance. As a result, potentially responsive
(nontolerant) B cells would gain the capacity to
produce autoantibodies. Thus, viruses might act as
adjuvants for autoantibody formation by stimulating
sensitized T cells to produce helper substances,
which could then stimulate B cells to produce autoantibody in the presence of autoantigen. They could
also interfere in some unexplained manner with the
suppressor effect of suppressor T cells by producing
a broad interference with T cell function since, as
mentioned, T cell levels are, in fact, low in the virus
diseases ( 7 ) .
Another interesting line of evidence which
should be mentioned comes from the studies of
Lewis and co-workers (22) who have injected
filtered suspensions of spleens of dogs with SLE
to CA F 1 mice. These mice have, as a result, developed antinuclear antibodies. This finding suggests
the presence of a filterable agent, probably a virus,
in the affected donor dogs, having the capacity to
produce antinuclear antibodies.
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The "Three R's" of Delayed Hypersensitivity*
DAVID HORWITZ, M.D.

Associate Professor, Rheumatology Division, Department of
Internal Medicine, University of Virginia School of Medicine,
Charlottesville

Delayed hypersensitivity is one of several immune responses initiated by thymus-derived (T)
lyrriphocytes. Other functions of T cells are listed
in Table . 1 and summarized in reference 1. The
mononuclear infiltrate of delayed hypersensitivity is
a collaborative phenomenon between T lymphocytes
and monocytes. This collaboration can be separated
into components which I have chosen t6 call the
"three R's'~ of delayed hypersensitivity. In this discussion I will define these "three R's" and examine
the usefulness of this concept in clinical medicine.
Hematoxylin and eosin sections of skin biopsied
48 hours after intradermal injections of antigen
characteristically show mononuclear cells around
blood vessels and in connective tissue. As early as
1951, however, Gell and Hinde (2) reported that
the monocyte was the principal participant in the
skin site. In 1963, McCluskey (3), using radioisotopic techniques, found that 90% of the mononuclear cells in the reaction site were blood-borne
and originated from cells that had divided 48 hours
previously. Subsequently, cell transfer studies have
provided conclusive evidence that the rapidly dividing cells originated in the bone marrow and were
precursors of the blood monocyte. Tiie evidence is
as follows: 1) Injection of immune lymphocytes into
nonimmune, irradiated recipients failed to transfer
positive skin reactions ( 4); 2) Injection of bone
marrow cells from nonimmune donors to sensitized,
irradiated animals resulted in positive responses ( 5);
3) Local injection of nonimmune macrophages into
the skin of irradiated, sensitized recipients elicited
positive responses in these areas ( 6).
These studies indicated that two populations of
cells are required to elicit delayed hypersensitivity.

* Presented by Dr. Horwitz at the 45th Annual
McGuire Lecture Series, November 8, 1973, at the Medical
College of Virginia, Richmond.
MCV QUARTERLY 10(2) : 61 ·64. 1974

The first are radioresistant, which were later defined
as long-lived, T lymphocytes. The second population
are cells of the monocyte/ macrophage system and
are derived from radiosensitive precursors in the
bone marrow.
From this information we can develop a concept of delayed hypersensitivity consisting of three
components (Table 2). First, sensitized T lympho~
cytes, perhaps with some help from macrophages,
recognize intradermally injected antigen. Secondly,
antigenic contact triggers a response in sensitized
lymphocytes. Within a few hours these cells release
soluble mediators (7) called Iymphokines into the
environment and later, activated small lyrriphocytes
transform into blasts and proliferate. Thirdly, through
the amplifying effects of lymphokines, such as migration inhibitory factor (MIF) and monocyte chemotactic factor (MCF), other leukocytes, predominantly
monocytes, accumulate at the skin .test site and
comprise the reaction of delayed hypersensitivity.
This mononuclear infiltrate is similar to that of any
other chronic inflammatory reaction. The triggering
event, however, is an immunologically specific response of T lymphocytes.
Techniques are available to evaluate each of the
"three R's." The number of circulating T cells available for antigen recognition can be quantitated by
several methods. The most widely used method at
this time is a rosette technique. When sheep erythrocytes are incubated with human lymphocytes at 4 °C,
the erythrocytes form rosettes around T cells ( 8).
Secondly, heterologous anti-T lymphocyte serum has
been developed (9) and may be used to quantitate
T cells either by immunofluorescence or cytotoxicity.
The second component, response to antigen,
can be evaluated by measuring the lymphocyte pro~
Iiferative response to antigen. In these studies
lymphocytes are cultured with test antigen for five61
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TABLE 1
THYMUS-DERIVED LYMPHOCYTE FUNCTIONS

1.
2.
3.
4.

Delayed hypersensitivity
Activation of macrophages to resist infection
Rejection of allografts and tumors
Regulation of antibody production by B cells

to-seven days and proliferation is assayed by measuring incorporation of a radiolabeled DNA precursor.
Alternatively, one can measure lymphokine
production from antigenically stimulated lymphocytes. Migration inhibitory factor has received the
most attention (7). Various techniques to measure
MIF have been developed which are based on the
inhibition of leukocyte migration by the culture
supernatants of stimulated lymphocytes. The method
of Rocklin and David (10) correlates well with
delayed hypersensitivity. These workers use guinea
pig peritoneal macrophages as effector cells. Other
workers have substituted human "buffy coat" leukocytes for guinea pig macrophages ( 11 ) . Results
obtained with these cells as the indicator cells, however, did not always correlate with cutaneous skin
reactivity to antigen (12).
I prefer to measure MCF rather than MIF,
because both response and reaction can be evaluated.
With this technique we can detect mediator production from a given patient's lymphocytes and also
evaluate the capacity of that subject's monocytes to
respond to bis own mediator. With a method to

measure leukocyte chemotaxis, we can evaluate both
lymphocyte and monocyte function.
To perform this technique a chamber is divided
into an upper and lower compartment by Nuclepore®
membrane. Monocytes are placed in the upper chamber and the chemotactic stimulants in the lower
chamber. The specific migration of cells from the
upper to the lower surface of the membrane filter
is quantitated ( 13).
These in vitro methods can be used to define
the component that is defective in patients with
impaired delayed hypersensitivity. Lymphocytes from
children with a congenitally absent thymus gland
(the DiGeorge syndrome and Nezelof syndrome)
fail to form rosettes with sheep erythrocytes or to
proliferate in response to mitogens. These children,
then, do not have sufficient T lymphocytes capable
of antigenic recognition.
Impaired cell-mediated immunity in chronic
mucocutaneous candidiasis may be due to several
defects, either .in a response or reaction. Patients
with this disease usually have adequate numbers of
circulating lymphocytes but may have selective defects in lymphocyte or monocyte function. In some
subjects, blast transformation is intact but MIF is
absent ( 14). In others, mediator production is intact,
but these patients' lymphocytes fail to proliferate in
response to antigen (15). Finally, Snyderman (16)
reported a patient with chronic mucocutaneous candidiasis whose monocytes responded poorly to a
chemotactic stimulus. Although it is tempting to
speculate that the defects detected with in vitro

TABLE2
DELAYED HYPERSENSITIVITY
A COLLABORATIVE PARTICIPATION OF LYMPHOCYTES AND MACROPHAGES
IN AN IMMUNOLOGICALLY SPECIFIC INFLAMMATORY REACTION
Component
Assay System

1. The recognition by small (thymus-derived)
Quantitation of T lymphocytes by:
1. Spontaneous rosettes without sheep erythrocytes.
lymphocytes of material which is antigenic to the host.
2. lmmunofluorescence or cytotoxicity using heterologous
antihuman thymocyte serum.
2. A response of sensitized lymphocytes as detected by the
release of soluble factors (lymphokines) and later by
cell division.

Generation of lymphokines
1. Migration inhibitory factor (MIF)
2. Macrophage chemotactic factor (MCF)
Blast transformation and proliferation

3. A mononuclear inflammatory reaction, consisting
predominantly of "activated" macrophages, which
leads to the attack, destruction, and sequestration of
autologous or foreign materials.

Monocyte response to MCF
"Skin-window" assay

HORWITZ: "THREE R's" OF DELAYED HYPERSENSITIVITY

techniques accurately reflect an in vivo disturbance,
the data must be interpreted with appropriate caution
at this time.
Delayed hypersensitivity may be impaired in
conditions without a demonstrable defect in cellular
function . Serum factors inhibit lymphocyte function
in certain diseases and several examples are listed
in Table 3. The role of these serum inhibitors has
not been defined. Moreover, primary disorders of
lymphocyte function have not been differentiated
from secondary effects caused by serum factor in
many diseases with impaired cellular immunity.
Recent studies from this laboratory suggest that
anergy in such diverse diseases as systemic lupus
erythematosus (SLE) and primary intracranial tumors ( 17) is caused by serum inhibitors rather than
defective cells. Fractionation of inhibitory serum
in patients with each of these diseases revealed an
IgG factor that broadly suppresses reactivity of
allogeneic as well as autologous lymphocytes. This
inhibitory lgG factor has been named lymphocyte
regulatory immunoglobulin (LRG) and increased
LRG in SLE may, in part, explain decreased delayed
hypersensitivity. Patients with SLE and other diseases also have a lymphocytotoxic antibody that
may depress cell function.
In summary, I have attempted to develop a
working model of delayed hypersensitivity that may
be useful in understanding areas puzzling to the nonimmunologist. The reader is urged to ask the following questions in order to evaluate scientific papers
dealing with defective cellular immunity in various
diseases. First, did the patients studied have adequate
numbers of circulating lymphocytes and monocytes?
Secondly, did the methods used evaluate a single
component of delayed hypersensitivity or were several components analyzed? Finally, did the authors
distinguish a primary cellular defect from secondary

TABLE 3
DISEASES WITH SERUM INHIBITORS OF LYMPHOCYTE FUNCTION
1.
2.
3.
4.
5.
6.
7.
8.
9.

Hematologic and solid tumors
Systemic lupus erythematosus
Tuberculosis
Multiple sclerosis
Hepatitis
Lepromatous leprosy
Ataxia telangiectasia
Multiparous women
Multiple transfusions
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humoral effects? Separation of delayed hypersensitivity into "three R's" may be helpful in organizing
and understanding present information.
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Immune Comp.lex Reactions in Systemic Lupus
Erythematosus*
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Rheumatology, University of Virginia School of Medicine,
Charlottesville

We should first try to define systemic lupus
erythematosus (SLE). Table 1 lists criteria proposed
by a committee of the American Rheumatism Association ( 1). If four of these 14 major criteria are
positive, then there should be about 98% specificity
for SLE. There are clearly many facets to this disorder. Let us consider mechanisms that might account for a multisystem disease such as this.
A good model is that of experimental serum
sickness. Though Germuth (2) provided much of
the renewed impetus to study serum sickness in the
'SO's, it is Dixon (3) who has fully explored the
variables of immune complexes and disease.
When a rabbit is given a single intravenous
injection of bovine serum albumin (BSA) labelled
with 1811, one notes disappearance of the BSA in
serum over a period of about 13 days. First there
is a rapid fall, then an equilibrium dev~lops; and
then suddenly there is total disappearance of the
injected BSA. Coincident with the rapid disappearance of BSA, one can measure antigen-antibody
complexes. Finally, free antibody to BSA is detected.
During the period when these immune complexes are
found, the rabbits develop heart disease, arthritis,
nephritis, and other manifestations. It is a selflimited disease, however, and when free antibody
is found the disease clears up. Hemolytic complement (C) has been measured also; with the appearance of immune complexes, the C level falls, later
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of Virginia, Richmond.
**Supported in part by the USPHS Grant No. 5R01AM11766 and a grant from the John A. Hartford Foundation, Inc.
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returning to normal. This then is the model of
experimental serum sickness in the rabbit; what
about immune complexes in man?
We are postulating that many manifestations
of SLE probably result from deposition of circulating
immune complexes. Numerous data are now available which would support this concept. What can
we now do to find these eomplexes and characterize
them? If we can show what is in these complexes,
we should know something more about pathogenesis.
Table 2 lists some of the methods that are
available today. These methods are mostly limited
to research laboratories. I have listed these methods
as either analytical or preparative. Cryoprecipitation
is both analytical and preparative; furthermore,
cryoprecipitates are easily measured since all one
needs is a refrigerator and a centrifuge. Recent
studies by Mcintosh et al. ( 4) suggest that cryoprecipitates correlate well with immune complex
formation in rabbits; evidence in man is not as
convincing since it is difficult to recover a specific
pathogenetic antigen in SLE cryoprecipitates.
Clq precipitation was first described by Agnello
et al. (5); here one utilizes purified Clq to precipitate with serum factors in double diffusion
systems. Rheumatoid factor (RF) can be used in
the same way. Efforts in our lab are now being
directed toward an analysis of the characteristics of
Clq reactive factors. It is of interest that Clq and RF
seem to detect different substances in serum. Passive
agglutination of RF-coated cells is another method
which detects complexes, as is complement fixation
(which is a way of interpreting "anticomplementary
serum"). Recent work in England has shown complement fixation and Clq precipitins not only in
65
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TABLE 1
PRELIMINARY CRITERIA FOR CLASSIFICATION OF SLE
!. Facial Erythema (Butterfly Rash)

2.
3.
4.
5.
6.
7.

8.
9.
10.
11.
12.
13.
14.

Discoid Lupus
Raynaud's Phenomenon
Alopecia
Photosensitivity
Oral or Nasopharyngeal Ulceration
Arthritis without Deformity. [One or more peripheral
joints involved with any of the following in the absence
of deformity: a) Pain on motion, b) Tenderness, c)
Effusion or periarticular soft tissue swelling.]
LE Cells
Chronic False-Positive STS
Profuse Proteinuria
Cellular Casts
One or both of the following: a) Pleuritis, b) Pericarditis
One or both of the following: a) Psychosis, b)
Convulsions
One or more of the following: a) Hemolytic anemia, b)
Leukopenia c) Thrombocytopenia

SLE serum but in sera from patients with dermatitis
herpetiformis, ulcerative colitis, regional enteritis,
and coeliac disease ( 6, 7). Lymphocyte inhibition
is another technique recently reported: B cells,
which kill sensitized tumor cells, are inhibited by
serum containing aggregates or immune complexes
( 8). Platelets can also be agglutinated by complexes.
Cryoprecipitation is, at the same time, a preparative method. Likewise Clq can be linked to
Sepharose® columns through cyanogen bromide to
facilitate removal of Clq precipitins from serum for
analysis (9). Hopefully, the immune complexes and/
or aggregates will stick and everything else will wash
through; then the bound material can be eluted off

with salt and the residue analyzed. Serum can also
be run directly through agarose columns with exclusion of large molecular weight materials. In summary, the main point here is that many methods are
being developed to find and characterize aggregates
and complexes; the simplest method is probably
cryoprecipitation.
Figure 1 shows various factors which we measured longitudinally in one SLE patient several years
ago. The relationship between serum cryoglobulins
and C levels is particularly noteworthy (our normal
range for serum hemolytic complement is 34-48
CH50 units/ ml) and one can clearly see the reciprocal relationship between C and cryoglobulin
during the time span. This negative correlation is
not always seen but usually is.
Figure 2 shows findings in another patient.
Here the C level is first found in the normal range
at a time when no cryoglobulins are seen. As the
cryoglobulins appear, C levels begin to fall. It should
also be noted that the antinuclear factor (ANF)
remained fairly constant during this time period,
though no titers were done. It has been our experience that when we use a 1 :4 dilution of serum for
the ANF test, little change in ANF can be noted
between acute exacerbations and remissions of SLE.
With prolonged remission, however, the staining may
become less intense, though the ANF rarely disappears entirely in SLE patients. RF titers (usually
low titers, when found) also tend to remain quite
constant in SLE patients, though RF was not found
in either of the patients shown in these figures.
Lupus Patient Ca
4+

ANF [

4+

4+ 4+ 4+

3+

4+ 4+ 4 + 4+ 4+

RF

0
····· ~

so

0

0

0

0

CRYOGLOBULIN

0-----0 COMPLEMENT

40

4+

30

3+

20

2+

10

1+

PROTEINURIA

li!l

6 ······6····4

TABLE2
DETECTION OF CIRCULATING IMMUNE COMPLEXES AND / OR
AGGREGATES
Analytical
Cryoprecipitation
Clq detection in agarose gel
RF detection in agarose gel
or reverse hemagglutination
Complement fixation
Lymphocyte inhibition
Platelet agglutination

c

Cryo

Proteinurio

Preparative
Cryoprecipitation
Cl q precipitation
Adsorption to columns of
insoluble Clq

I
--

12
1968

1

2

3

4

s

6

7

8

9

2

3

Ir

4

1970

1969

Months

Isolation by column
chromatography

Fig. I-Laboratory findings in a patient with SLE over a
16-month period. The reciprocal relationship between C
and cryoglobulins is noteworthy. Antinuclear factor and
proteinuria are relatively stable during this time.
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lupus Patient Wa
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TABLE 4

4+ 4+

Clq PRECIPITINS

0 0

"

so

······O. CRYOGLOSULIN
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4+
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PROTE1NURIA
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c
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Proteinuria
4+
3+
2+
I+

12

I

2

3

4

1968

5

6
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12

I

2

3

4

S

Total Sera (106)
Lupus Sera (74)
Other Sera (32)
Cryoglobulins (106)
Cryo. Supernatants (106)
Lupus (74)
Other Sera (32)

16
11

5
0
24
18
6

3

Positive
15
15
16
0
23
24
19

6

1970

1969

Months

Fig. 2-Laboratory findings in another patient with SLE.
Very little proteinuria is noted even when the C level is
low and large amounts of cryoglobulin are found.

Clq precipitins have been found primarily in
SLE patients with low serum C levels according tb
one report (10) . In a group of 30 SLE patients with
low C levels, 23 were positive for Clq precipitins;
of those SLE patients who had normal C levels none
were positive for Clq precipitins. A few p~tients
with miscellaneous diseases were positive ( 6/ 150) .
Table 3 shows our results: Of 908 total sera
tested for Cl q precipitins, 19 % were positive. (These
sera came from patients who had a variety of diseases
and were mainly suspected of having a connective
tissue disease or vasculitis.) Of the lupus sera, 15 %
were positive and of the lupus patients, 43 % were
positive on at least one occasion. Sera from patients
with other diseases were positive 27 % of the time,
the 28 % positivity of nonlupus patients reflecting
the fact that many of these patients were only
studied by this technique on one occasion . Of particular note is the finding of Clq precipitins in other
diseases besides SLE-a finding supported by other
investigators ( 6, 7, 10) .

TABLE 3
Clq PRECIPITATION

Total Sera
Lupus Sera
Lupus patients
Other Sera
Other patients

CRYOGLOBULINS
# Positive

o--o COMPLEMENT

lftA

VS.

Total

#Positive

908
601
95
307
216

174
90
41
84
61

3

Positive
19
15
43
27
28

Results of the Clq precipitin test as it relates
to sera with cryoglobulins ate shown in Table 4.
One notes that of the 160 sera tested here, 16 were
positive for Clq precipitins; aild of these 16 sera,
11 were SLE seta and 5 were other disease sera.
Only some of these sera had cryoglobulins, but we
treated them all as if they did-that is, they were all
centrifuged after 48 hours in the cold and the supernatant transferred to another tube for testing against
Clq. The cryoprecipitates, whether visible or not,
were resolubilized at a ten-fold concentration and
also retested against Clq. No cryoprecipitates showed
a precipitin line, suggesting that 1 ) there was not
enough material, 2) the material did not react with
Clq, or 3) that the cryoprecipitate was already saturated with bound Clq. Of more importance, however, was the finding that of the 106 supernatants,
24 (instead of 16) were now positive. Ali of the
16 sera which were positive originally remained positive when the supernatant was checked and eight
sera which were originally thought to be negative
were now positive after removal of any cryoprecipitates. These studies have suggested to us that cryoglobulins have properties, at least in part, distinctive
from Clq precipitins. Possibly the cooling and centrifugation of certain sera lead to aggregation of small
complexes that do not spin down as cryoglobulins,
but do subsequently react with Clq, even at room
temperature!
For several years, we have been interested in
how RF might modify IgG aggregates or immune
complexes in human disease ( 11, 12). We have
wondered whether RF might affect the deposition
or metabolism of complexes by changing their size
or their physicochemical properties in some other
way. Small, soluble complexes might be made insoluble by RF; this might serve a protective function
or a pathogenetic function depending on the circum-
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Precipitation of 3H-DNA
by SLE Serum with RF-lgM and Controls
4,000
- R f.lgM
<>--o C·lgM
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0.05 ml SLE serum
(F.W. 8/ 12/ 70)

.,
~

0-

·=
::;:

2,0 00

"u

1.0 00

1.25

2.5

5.0

10

20

50

100

would precipitate at equivalence but would resohibilize in both antigen and antibody excess.
Table 5 shows the sort of data being accumulated currently on patients seen at the University qf
Virginia Lupus Clinic. In the serum of this patient
before treatment, a Clq precipitin was found, along
with 3+ cryoglobulins, strong anti~DNA activity, a
low C level, and strong ANF staining: After institution of steroid treatment, the Clq precipitin disappeared, but then we found material in the serum
reacting with RF! (This often-seen reciprocal relation is of great interest to us, but we don't understand it.) Cryoglobulins disappeared (as did the
anti-DNA antibodies) and at the same time the
serum C level returned to normal. Since starting
treatment, the patient has done well, and we have
continued to be on the lookout for. the reappearance
of those factors associated with disease activity as
we slowly lower the steroid dose.
Table 6 is an analysis of serum material bound
to Clq on a cyanogen bromide Sepharose® column.

micrograms DNA
Fig. 3-Effect of lgM rheumatoid factor on bNA-antiDNA complexes. Constant amounts of IgM [either control
(C) or containing rheumatoid factor (RF)] are added to
constant amounts of anti-DNA (SLE) serum and increasing
amounts of . DNA. Much more radioactive DNA is found
in the precipitate when RF is added than in appropriate
control systems.

Cryoglobulin in Lupus Sero before
ond after addition of RF
(lml RF added to 2ml Lupus Sera)
1.2
Ca

(1 / 8 / 70)

Wa

1.05

(1 / 8 / 70 )

0 .9

stances ( 13). Figure 3 shows that RF has the
capability of precipitating partially soluble DNAanti-DNA complexes form!!d in vitro when one adds
increasing amounts of ~abelled DNA to an SLE
serum. It can be seen that much more precipitate
is formed (based on counts of radioactive DNA in
the precipitate) in the presence of RF than whert
the complexes are formed in the presence of controllgM or buffer alone. We interpret these findings to
mean that RF can interact with and precipitate
DNA-anti-DNA complexes, thus converting these
partially soluble complexes into insoluble complexes.
As mentioned above, such a function for RF in vivo
could be either protective or damagihg.
Figure 4 shows effects of RF on cryoprecipitates.
It would appear that RF has the potential for either
increasing or decreasing cryoprecipitation, probably
depending on characteristics of the cryoprecipitate.
Conceivably one might be dealing with a system
analagous to an antigen-antibody complex which

mg. of o.6
Cryoprotein

0 .3

0.15

Cryo Cryo

+
RF

Cryo Cryo

+
RF

Cryo Cryo

+

RF

Fig. 4-Effect of lgM rheumatoid factor on three SLE sera
containing cryoglobulins. After addition of RF to fresh sera
Sn and Wa, less cryoglobulin was detected after 48 hours
at 4°C; when RF was added to serum Ca, however, more
cryoprotein was detected.
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TABLE 5
S. P. (SLE)

Complexes
Clq

4/6/72
Treatment Started
4/ 11 / 72
4/ 13 / 72
4/ 17 / 72
4 /21/72
5/ 2/ 72
6/13/72
7 / 25 / 72
11 / 21 / 72
* ND

=

RF

Cryo

Anti-DNA

3+

3+

4+

ND*
ND
ND
1-2+
2+

3+
2-3+
2-3+
2+

ND
ND
ND
1-2+
ND
3+
3-4+
3-4+

+
+
+

CH50

10

13
ND
ND
ND
40
53
48
45

Not Done

One notes the presence in the two eluates of IgG
and IgM but no anti-DNA or DNA. Currently, we are
analyzing these eluates by a variety of techniques including animal immunizations (to elicit antibodies to
any infectious agents which might be there). Charactedstics of Clq precipitins are also being compared
with characteristics of cryoglobulins. It should be
noted at this point that normal serum also contains
significant amounts of material which bind to the
Clq adsorbent.
In summary, we can draw very few firm conclusions about immune complexes in patients with
SLE. SLE patients during episodes of disease activity
often show both cryoglobulins anq Clq precipitins
in their sera, but in our experience, the sera may
show only one of the factors and occasionally neither
one is found. When cryoglobulins are removed from
sera, Clq precipitins not only remain in the supernatant but occasionally may be found in the super-

TABLE 6
ANALYSIS OF ELUATES BOUND TO INSOLUBLE CIQ

lgG (mg)
lgM (mg)
IgA (mg)
Clq
DNA
Anti-DNA
RF
Pptns. vs Clq

ANF

E.F. (SLE)*

J.D. (N)**

3. 12
0 .49
0
+

0 . 73
0 . 31
0
Trace

1:8
+

1 :8
+

* SLE = Lupus serum eluate
** N = Normal serum eluate

natant for the first time. This finding suggests that
cryoglobulins and Clq precipitins are at least in part
distinct. RF may interact with DNA-anti-DNA complexes and cryoprecipitates at ·least in vitro. Studies
are in progress to furtfler characterize the material
found in, the~e complexes. Hopefully, a particular
antigen or a particular characteristic of SLE complexes will be found which will lead to a better
understanding of the primary cause and intermediate
mechanisms involved in the serious disease kriown
as SLE.
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Within the last few years, the study of ankylosing spondylitis has produced some of the more
remarkable new developments in the field of the
rheumatic diseases. In modern days the disease has
been described in Germany by Striimpell and in
France by Marie. As a result, in Germany it is
known as Striimpell's disease and in France as
Marie's disease. Physicians in the United States and
England, to be fair, call it Marie-Striimpell disease.
It should be emphasized at this point that ankylosing
spondylitis is not a variant of rheumatoid arthritis
as it had been considered for a number of years.
The term rheumatoid spondylitis is still occasionally
used but should be completely abandoned.
The initial diagnosis of ankylosing spondylitis
is often a difficult one to make. The best criteria we
have are quite simple. They are 1) limitation of
motion of the lumbar spine; 2) pain in the low back;
and 3) limitation of chest expansion. As you can
see, no laboratory tests except the x-ray film are
used and in the early stages, x-ray film examination
may not be helpful.
Examination of the lumbar spine in some studies
shows that limitation of extension may actually be
a better way of separating normal from abnormal
spines ( 1), although limitation of flex ion (flattening
of the lumbar curve) is usually what we look for
in the back examination. Moll and Wright (2) have
shown that lateral spinal flexion is the best way
to distinguish between spondylitis and lumbar disc
disease. Spondylitis will also cause limitation in this
direction.
The erythrocyte sedimentation rate can be
normal in patients with ankylosing spondylitis.
Even patients with rather marked degrees of pain
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can have normal sedimentation rates while patients
who may just show changes in the sacroiliac, hips,
or back without pain can have a significantly elevated
sedimentation rate. Of course, rheumatoid factor is
not found in these patients and can be of diagnostic
help only by its absence.
The patient with ankylosing spondylitis is
usually a young white male who gives a fairly
typical story. Back pain usually wakes him up in
the small hours of the morning. It is rare that he
will complain of being unable to go to sleep because
of pain. He will usually awake because of discomfort in the lower back and get out of bed. He may
get relief (and go back to sleep) lying on the floor
or sitting up in a hard back chair or sitting on the
floor with his back against the wall. The pain frequently, as with sciatica, goes down the back of the
legs. Alternation of the radiating pain from one side
to the other is a typical feature which helps to
distinguish the symptoms from those produced by a
lumbar disc protrusion.
Examination of the x-ray films may initially
show erosions in the sacroiliac joints and finally
fusion, and of course, the "bamboo" spine of late
disease is well known. The development of the
changes in the spine can be shown diagrammatically
so one can differentiate the syndesmophyte of ankylosing spondylitis from the osteophyte of degenerative joint disease (Fig. 1). This is taken from a
recent article of Riley, Ansell, and Bywaters (3).
On the left in the figure is seen the progression of
osteophytosis and on the right, the progression of
syndesmophytosis. The osteophyte is associated with
disc narrowing. The bony plate is marginal and most
importantly is horizontal as seen in stages three and
four. It is built up at the base with subperiosteal
bone. The base appears to lie against protruded
disc substance. In ankylosing spondylitis, there is no
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went on to adulthood, developed typical ankylosing
spondylitis.
Joint involvement in ankylosing spondylitis is,
of course, different from that seen in patients with
rheumatoid arthritis. Forestier ( 4) showed (Table
1) the high frequency of hip involvement in this
disease when compared to patients with rheumatoid
arthritis. In the rheumatoid, there is much more
peripheral joint involvement.
There are a number of complications which
are more specific and more frequent in ankylosing
spondylitis than in many of the other forms of
arthritis. Most of the complications that have been
noted are listed in Table 2. Iritis is said to occur in
up to 20% of patients. Aortic insufficiency is usually
seen quite late in the disease. Heart block is rarely
seen but also probably represents the same type of
inflammatory action in the myocardium as is seen
in the aorta. Amyloidosis, again, is not seen
frequently but is a recognized cause of death in
ankylosing spondylitis-certainly more so than with
rheumatoid arthritis. Atlantoaxial subluxation is a
constant threat to these people with spine fusion and
can sometimes be fatal after only moderate degrees
of trauma. Cauda equina involvement is rarely seen
but, again, is a well-recognized problem. Pulmonary
fibrosis of the upper lobe is of interest because this
fibrosis, which may be typical of spondylitics, has
been mistaken for tumor, tuberculosis, and the like.
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Reprinted by permission from Ann Rheum Dis (3 ) .
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disc narrowing or protrusion. A vertical plate is
built up in the outer layer of the annulus fibrosis.
These syndesmophytes will ultimately bridge in stage
IV of the disease.
Ankylosing spondylitis is a disease of young
males, seen in Figure 2 where the peak in a large
series is found to occur in the late teens and early
20's (4, pg. 10). There is, however, a group of
ankylosing spondylitics who start at an earlier age.
Barbara Ansell and Eric Bywaters in Taplow, Eng··
land followed up 139 patients with juvenile rheumatoid arthritis (JRA), 55 males and 84 females, for
at least 15 years into adult life. What was striking
about the 55 males was that 9 % of them, as they
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From Forestier, J . et al., ( 4) . Courtesy of Charles
C Thomas, Publisher, Springfield, Illinois.
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TABLE 1

TABLE 2

PERIPHERAL JOINT INVOLVEMENT AT ONSET*

Ankylosing
Spondylitis
(200 patients)

Rheumatoid
Arthritis
(100 patients)

Joint

%

%

Hips
Knees
Ankles
Feet
Shoulders
Elbows
Wrists
Hands
Temperomandibular
Sternoclavicular

42
29
7
12
30
3
5
7
6
11

10
62
58
28
64
46
82
94
8
7

* After Forestier (4)
It probably accounts for some of the earlier state-

ments made about the higher frequency of tuberculosis in these patients. It is remarkable how good
pulmonary function is in these men with limited
chest expansion. A recent study indicates that impairment of lung function is minimal in most of the
patients with this disease ( 5).
The variants of ankylosing spondylitis are shown
in Table 3. All of these conditions can show sacroiliitis and indeed in some cases, go on to more extensive spinal involvement quite similar to those seen in
ankylosing spondylitis. I will mention some of these
again later because of an interesting relationship.
For many years, it has been felt that there were
strong genetic features connected with ankylosing
spondylitis. Several years ago, when I was still in
Dallas, Morris Ziff and I, seeing our patients at
the Veterans Administration Hospital, were struck
by the relative rarity of ankylosing spondylitis among
our black patients. (One of the earliest clinicians
to note this rarity was Elam Toone in 1949.)
He found, in a group of patients that he was
studying in the McGuire Veterans Administration
Hospital in Richmond, 26 white and only three
black patients with ankylosing spondylitis ( 6). Table
4 shows what we found in Dallas at the Veterans
Hospital when we looked at the frequency of ankylosing spondylitis in relation to a number of other
disease admissions rates and the male population of
Dallas ( 7). As you can see, although the admission
rate to the Veterans Hospital clearly reflected the
racial distribution of the population, there was a
marked discrepancy in the relative ratio of patients

COMPLICATION~ OF ANKYLOSING SPONDYLITIS

Iritis
Aortic Insufficiency (Aortitis)
Heart Block (Myocarditis)
Amyloidosis
Atlantoaxial Subluxation
Cauda Equina Involvement
Upper Lobe Fibrosis

with ankylosing spondylitis. We were not satisfied
with this view, thinking perhaps we might have an
unusual situation. When data were pooled from a
number of VA hospitals, we found a fourfold difference in the frequency of ankylosing spondylitis
between whites and blacks. A search of the African
literature showed that there are virtually no patients
with ankylosing spondylitis in Africa among the
black native population. A review of genetic studies
in the United States indicated that the black population of the United States has a 20-25 % admixture
of white genes. This admixture of white genes would
very nicely account for the fact that ankylosing
spondylitis was only found in about 20-25% of
the expected frequency, if it had the same distribution in the blacks as it did in whites.
This information was subsequently utilized by
Schlosstein, Terasaki, Bluestone, and Pearson ( 8)
at the Wadsworth VA Hospital in Los Angeles.
The transplantation antigen known as W-27 was
found in 8% of a caucasian population but was
found in 88% of a group of patients with ankylosing
spondylitis. It was also interesting to note that W-27
is not found in Black Africans and is present in an
approximate frequency of 4% in Black Americans.
To further support the relationship of this antigen to
ankylosing spondylitis, W-27 was found in eight of
ten Black Americans with ankylosing spondylitis.
Another and perhaps more striking correlary of

TABLE 3
VARIANTS OF ANKYLOSING SPONDYLITIS

Psoriatic Arthritis
Ulcerative Colitis
Crohn's Disease
Whipple's Disease
Behcet's Disease
Reiter's Disease
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TABLE4
RACIAL DISTRIBUTION OF ADMISSIONS AND OF ANKYLOSING SPONDYLITIS, RHEUMATOID ARTHRITIS, AND REITER'S SYNDROME AT
DALLAS VETERANS ADMINISTRATION HOSPITAL
Number White Number Black
Males-Dallas, Texas (1960 census)
Male Admissions (10 months, 1966)
Ankylosing Spondylitis (1959- 1966)
Rheumatoid Arthritis (1959- 1966)
Reiter's Syndrome (1959- 1966)

263,354
5 , 182
41
90
7

this data was recently presented by Rodney Bluestone of this group at the XIIIth International Congress of Rheumatology in Kyoto, Japan (9). In
Table 5 are seen their most recent data. As you can
see, W-27 is found in 14 of 156 patients with
psoriasis alone. This is just about the frequency found
in the normal population; however, in those patients
with psoriasis who develop spondylitis it has been
found in four of six individuals. In patients with
colitis who developed spondylitis, this high frequency
was again found. Perhaps even more remarkable are
15 out of 16 juvenile rheumatoid arthritics with W-27
who had spondylitis. Chronic Reiter's syndrome had
the W-27 antigen in every case. Perhaps more
astonishing were the studies they subsequently did
looking at patients with acute Reiter's syndrome.
Even those who do not have spondylitis showed
W-27 in a remarkably high frequency.
We now seem to have a new tool for the diagnosis of some forms of arthritis. For example, in
male children who develop what appears to be
juvenile rheumatoid arthritis, looking for W-27 might
give us a strong clue as to the future course of their
disease. A similar use could be in suspected Reiter's
syndrome. This has certainly opened the door to a
most fascinating series of studies and conjectures

61, 911
1, 227
3
16
4

%

%

White

Black

81
81
93
85

19
19
7
15

White-Black
Ratio
4.2
4 .2
13 . 7
5.6
I. 8

about the relationship of the W-27 antigen and
spondylitis.
In the treatment of ankylosing spondylitis,
radiation therapy was at an early date, found to be
effective for relief of pain; it's use was given up
because of a reported high frequency of blood
dyscrasias following its application. There are still
some authors who feel that its limited use in patients
who are having pain in spite of other therapy is of
distinct benefit and of low risk ( 10). Indomethacin
and phenylbutazone are the most frequently used
drugs in the treatment of this disease. An observation was made recently that a patient with severe
ankylosing spondylitis who did not respond to the
above mentioned drugs responded quite well to
penicillamine therapy ( 11). Steroids are of little
use in this group of patients. Teaching the patients
exercises in an attempt to increase diaphragmatic
breathing is of benefit and exercises may sometimes
help to maintain the spine in better position.
It is worth noting that what we have learned
about this disease in recent years has provided us
with better methods of establishing the diagnosis and
prognosis of ankylosing spondylitis.
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Dr. Irby: For some time the influence of heredity in ankylosing spondylitis has been fairly well
established, but the exact mechanism has not been
understood. Although there has been some evidence
of familial clustering in peripheral rheumatoid arthritis, studies by Jacox and others in Rochester,
New York have indicated 25 of 28 siblings of
monozygotic twins to be discordant for rheumatoid
arthritis.
The subject of this discussion is HL-A antigens
* Presented at Medical Grand Rounds by the Dep;i.rtments of Medicine, Surgery, and Ophthalmology, January
29, 1974, at the Medical College of Virginia, Richmond.
**This is Publication No. 73 from the Charles W.
Thomas Arthritis Fund, Medical College of Virginia.
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and spondylitis. Since many people do not understand the language of the geneticists, Dr. James
Pierce will tell us what we need to know about HL-A
antigens. Questions that often arise include: 1) What
are HL-A antigens? 2) What is meant by HL-A 27?
3) How does one go about identifying antigenic
determinants in tissue typing?
Later we will try to document how some of
tqis material applies to many of the rheumatic diseases in which spondylitis is often a feature. In
conclusion, Dr. Macdonald of the Ophthalmology
Department will comment on various aspects of
anterior and posterior uveitis, how the diagnosis is
made, and what the treatment is of each. Uveitis is
often a complication of ankylosing spondylitis and
MCV QUARTERLY 10(2): 76-81. 1974
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Reiter's disease. A representative case involving
uveitis, arthritis, and the presence of HL-A 27 will
be reviewed.
Dr. Edwards: J. C. is a 30-year-old black male
who was first seen in the Emergency Room of the
Medical College of Virginia Hospitals on September
3, 1973. At that time, he complained of pain in his
back and left wrist. He stated that approximately
six days earlier, while doing manual labor, he had
experienced pain and swelling in his neck. The pain
migrated to his left hip, then between the scapulae,
and finally into the left wrist. Two weeks prior to
these complaints, he described a two day illness
characterized by diarrhea from which he recovered
with no therapy. Past medical history was significant
in that he had been treated five years earlier by his
local physician for a urethral discharge. There is no
family history of arthritis.
Physical examination at the onset of his illness
revealed a T 100.4 °F, P 104 per minute, and BP
120/74. There was pain in the area of the cervical
spine when his head was deviated to the right or
left. In addition there was tenderness to percussion
over the midthoracjc vertebrae, and a painful, warm,
swollen, erythematous left wrist. Also noted was a
small papular lesion on his left heel. An arthrocentesis of the wrist was unsuccessful. Laboratory
studies included a hemoglobin 16 gm%, WBC's
12,600 (78% polys, 13% lymphocytes, 9% monocytes), erythrocyte sedimentation rate (ESR) 15 m111
per hour (Wintrobe), and a urinalysis with a few
WBC's and RBC's but no protein, sugar, or acetone.
Repeat ESR's have been 30-40 mm per hour.
The following tests were either negative or normal:
rheumatoid pattern, antinuclear antibody, lupus
erythematosus cell preparations, antistreptolysin-0
titer, and urine and blood cultures. An intermediate
strength PPD was negative at 72 hours. Roentgenographic studies of his chest, cervical spine, thoracic
spine, and pelvis were normal. X-rays of the left
wrist showed soft tissue swelling only. Scrapings for
the papular lesion on his foot grew Trichophyton
mentagrophytes. HL-A 27 was found to be present
using the lymphocyte microcytotoxicity test.
Because of the concern that the patient was
suffering from an infectious arthritis, he was treated
with antibiotics. There was no response to this
therapy and by mid-September he had, in addition
to the left wrist, developed painful swelling of his
right ankle and pain to palpation in his right wrist.
Anti-inflammatory drugs, including salicylates, Buta-
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zolidin®, and gold, did not help. Colchicine was
likewise ineffective.
On October 8 he presented with an inflamed
and swollen right eye. Photophobia was present. An
ophthalmological consult found a visual acuity of
20/100 with a raised intraocular pressure in the right
eye. The left eye was normal. The etiology for this
nongranulomatous anterior uveitis was unknown but
felt to be related to the arthritis. Later a posterior
uveitis was also noted. Complete resolution of the
uveitis occurred over the ensuing six weeks, while
the patient was treated with alternate day corticosteroids ~n a progressively decreasing dose. The arthritis
also improved.
Subsequently the patient has complained of
left heel pain, yet no objective signs to document the
development of bony spurs have occurred. There is
no evidence of active synovitis although he does have
some limitation of motion of his right ankle and left
wrist. He denies any further back pain and is no
longer on any medications.
Dr. Irby: We are not at all sure of the exact
nature of this gentleman's illness. When the patient
was first seen on 'arthritis rounds, the lesions of his
foet were suggestive of keratoderma blennorrhagica.
1t' was felt that we were dealing with a case of
ankylosing spondylitis, possibly Reiter's spondylitis,
or seronegative rheumatoid arthritis. The latter diagnosis was entertained because of the lack of characteristic x-ray findings in the sacroiliac joints or
syndesmophytes on the margins of the lumbar spines.
After Trich9phyton mentagrophytes were cultured
from the patient's foot, the only things we had to
go on were the clinical picture of arthritis of an
asymmetrical nature, past history of urethritis, and
uveitis. Dr. Pierce's laboratory determined HL-A 27
to be present, so this gives us an opportunity to present recent data on the new trend in "spondylitisology," that of antigenic determinants by tissue typing
for the histocompatibility antigens.
Qr. Pierce: In my discussion of histocompatible
antigens, I want to review several things, such as
the rapidly changing development of this field, the
lymphocytotoxicity test-which provides a basis for
detecting these qntigens, some comments on the
genetics of inheritance of this system of antigens, the
nomenclature, a source of constant confusion, and
finally, the association of disease states with HL-A
antigens.
The field of histocompatibility typing began in
1954, when Dausset, in Paris, discovered that anti-
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bodies were present in the sera of patients who had
received multiple transfusions, which were directed
against leukocytes but not erythrocytes. In 1958
Payne and Rolfe at Stanford University found that
women who had had multiple pregnancies had similar antileukocyte antibodies. It was in this same year
that the first leukocyte antigen was discovered using
antisera, prepared from these patients, which had
reacted in common with leukocytes of certain other
patients. This particular antigen was HL-A 2 which
is the most frequent HL-A antigen found in Caucasians, being present in over 50% of a random population. A significant advance was made in 1964,
when Terasaki devised a microtest for detecting
these antigens. The advantage of the microtest over
the macrotest is that one thousand rather than ten
tests can be performed on one milliliter of serum.
A series of international workshops were held in
the late 1960's. In Torino in 1967, it was first reported that the HL-A antigens were inherited in a
Mendelian dominant fashion from parent to child.
The discovery that there are two HL-A loci relatively close together on an autosomal chromosome
was made in 1970 at the Los Angeles workshop.
The lymphocyte microcytotoxicity test detects
surface antigens of lymphocytes. These antigens
react with specific antibody to form a sensitized
lymphocyte which then reacts with rabbit complement. This results in the formation of holes in the
cell membrane of those lymphocytes with attached
antibody, allowing a dye to pass into the lymphocytes
that have been killed. Thus the dark cells seen via
the inverted phase microscope are dead cells containing dye. In a typical positive well, all the cells
will be dead. The antisera used for these reactions
are derived from multiparous women.
How are these antigens controlled genetically?
The genes for HL-A antigens are located on an autosomal chromosome, with each child receiving one
chromosome from his mother and one chromosome
from his father. Two loci controlling a different
series of antigens are located on each chromosome.
Therefore, there are two-to-four antigenic possibilities for each offspring. An individual with only two
HL-A antigens is rare, but this could occur if he
received an identical pair from his mother and
father. More common but still unusual and occurring
in 10% of the population is the presence of only
three HL-A antigens; the majority of people have
four HL-A antigens. One should distinguish between
the incidence of the antigens on a given chromo-

some, or gene frequency, and phenotypic frequency
which is the incidence actually observed in people.
The gene frequency of a given antigen is approximately one half the phenotype frequency. Because
they are inherited in a Mendelian dominant fashion,
there are four types of offspring with respect to HL-A
antigens that a pair of parents may have (Fig. 1).
Therefore, 25 % of siblings will be HL-A identical.
Also every child will share one haplotype, which is
one pair of antigens controlled by the two genes on
one chromosome with each parent. Therefore, a
child will share two of the antigens of his father
and he will usually have two additional antigens from
his mother which are different from those of his
father. There is also the chance, which is less than
1 :4, that a sibling will share no HL-A antigens with
another sibling.
What about the nomenclature of these antigens?
HL-A designates antigens recognized by the World
Health Organization Committee, which set up criteria for their identification. To be recognized, there
must be two monospecific antisera which define the
HL-A antigen and which do not overlap with other
recognizable HL-A antigens. Tentative recognition
is given to an antigen, when one monospecific serum
identifies it and many labs recognize it. This is
termed the W-classification system and what was
orginally designated W-27 is now designated HL-A
27. HL-A antigens have frequently been discovered
in a number of labs simultaneously, which has led to
confusion because they are given local designations.
For example, HL-A 5 has been designated by local
groups as AO 45, BT 25, 4C, TO 5, DA 5, and
TE 11. Obviously, it is easier to speak of HL-A 5,
so order is gradually coming into the field.
Where do we stand in discovering these antigens? In the first segregate series controlled by one
genetic locus, the gene frequency of those ten W
and HL-A antigens already discovered adds up to
0.978. If all antigens have been discovered, the gene
frequencies should add up to 1.00. On the second
segregate series, 15 W and HL-A antigens have been
discovered, but their gene frequency adds up to only
0.897, so approximately 10% of this group of HL-A
antigens remain undiscovered. There is a difference
in the racial distribution of these antigens. For example, HL-A 2 is found in 50% of Caucasians while
HL-A 9 is found in over 70% of Orientals. One can
see that a difference of gene frequency of these
HL-A antigens would provide a basis for difference
of disease incidence in different racial groups which
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Fig. 1-This illustration depicts a pair of autosomal chromosomes from each parent with the two HL-A loci on each
chromosome and the pattern of inheritance of the HL-A
antigens; 25% of the siblings will be HL-A identical.

is relevant to our patient today. The association of
HL-A 27 with ankylosing spondlylitis and with
Reiter's syndrome is striking.
Caution should be introduced, however, about
the association of an HL-A antigen and a disease
state. For example, some investigators have found
a significant association of HL-A 5 with Hodgkin's
disease while others have found no significant association at all. This is not very surprising, because
if 21 antigens are studied for association with a
disease, the chances are that one antigen will be
significantly associated with the disease by chance if
the level of significance is P = 0.05. Therefore, a
correction factor is introduced. The level of significance is divided by the number of antigens studied
in the search for an association. In the case of 21
antigens, the P value would have to be less than
0.0024 to have a significant association.
Two other points should be made about this
system of antigens-one is that HL-A antigens are
found on the surface of all somatic or nucleated cells,
so they are accessible to involvement with diseases;
secondly, this is the most polymorphic genetic
system found so far in man, so it lends itself to
individualization. Even though the incidence of a
disease may be very small, there is a real possibility
that it will be found associated with a given HL-A
antigen.
Dr. Irby: Although the possible association of
HL-A antigens with disease susceptibility has been
investigated for many years, it has been only within
the past two years that three convincing examples
have come to light (Table 1). In psoriasis, there is
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an increased disease incidence in first degree relatives and in adult celiac disease, the incidence in
relatives is six times normal. Patients with rheumatic
diseases have provided many interesting and significant correlations with HL-A antigens (Table 2).
Earlier studies and subsequent HL-A antigen investigators have demonstrated a striking relationship between HL-A 27 and ankylosing spondylitis and
between HL-A 27 and Reiter's syndrome (Tables
3, 4) .
Dr. Macdonald: Some years ago the principle
way of classifying uveitis was on the basis of granulomatous uveitis, in which th.e primary inflammatory cell was the epitheloid cell. · In the anterior
segment of the eye, the exudation was that of a
heavy proteinaceous material with many synechiae,
compared to the nongranulomatous variety, in
which the cell type was nonepitheloid with generally
a much less severe reaction. In the granulomatous
types of uveitis, or in iridocyclitis, the actual offending agent was considered to be present. For
some years, this classification was expounded by
Dr. Woods at Johns Hopkins University. At present,
uveitis is generally classified according to where it
is found in the eye, that is, anterior uveitis (involving
mainly the iris), both segments (involving the iris,
ciliary body, and choroid), and those involving only
the choroid. It is of particular interest that the leading cause of anterior segment disease is unknown; in
both segments, the third most common cause is unknown; and in the posterior or choroidal variety,
many are unknown. Much work remains in order to
properly determine the basic etiologies of uveitis. In
the anterior segment variety, ankylosing spondylitis
appears to be the third most common cause in this
series.
In the literature, a system for studying the
problem of sympathetic ophthalmia was propounded
by Elschnig in 1910. He proposed that melanins
in the uveal pigment of the eye where indeed the
exciting factors. The studies were carried out by
complement fixation tests. This has subsequently
raised the question of the role of melanin in the
eye. A further interesting question of the relationship of pigmentation in the skin to the VogtKayanagi-Harada syndrome of vitiligo, poliosis, a nd
dysacousis has been raised.
As we progress through clinical and research experiences, our concepts necessarily change. In 1941
Dr. Woods at Johns Hopkins reported a study of
343 cases of uveitis of which 80% were caused
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TABLE 1
HL-A ASSOCIATED WITH DISEASE*
Celiac Disease

HL-Al
HL-A8

2t-3 X Normal
3 X Normal

Stokes, 1972
Falchuk, 1972

Ch. Active Hepatitis

HL-Al
HL-A8

3 X Normal

Mackay, 1972

HL-A17
HL-A13

3 X Normal

Russell, 1972
White, 1973

HL-A27

10 X Normal

Psoriasis
Ankylosing Spondylitis

Schlosstein, 1973
Brewerton, 1973
Also some correlation lymphoma, multiple myeloma, SLE, and lymphoblastic leukemia with various phenotypes HL-A.
* The association of certain HL-A antigens with disease states has proven to be more than a chance correlation.

by tuberculosis. In 1960 Dr. Woods reported another series including 134 cases of uveitis. In this
study, only 20% of the cases were caused by
tuberculosis, whereas 36% were caused by toxoplasmosis, 13 % by histoplasmosis and 22 % were
of unknown etiology. Dr. Kaiser reported .a study
involving 110 patients with uveitis, and 38% of
these were caused by histoplasmosis which was the
largest single group. Much of this is, of course, attributable to the fact that Louisville lies in the Ohio
Valley which is endemic for Histoplasma capsulatum.
In our series of over 400 cases of uveitis, 60% have
been posterior (choroid), 18% anterior, 12% mid-

segment, and 10% involving all segments of the eye.
Approximately 58% of the cases of anterior uveitis
had an unknown etiology. There are probably two
reasons for this. First, there are many types of diseases which will produce a purely anterior uveitis.
Secondly, ophthalmologists are divided into two
groups-one group does everything diagnostically;
the second group treats them all with steroids and
a large majority get well anyway. Therefore, many
patients with the anterior uveitis appear to have no
known cause. In our group with anterior uveitis, there
were four cases of ulcerative colitis with spondylitis
( 6 % ) and six cases of Reiter's disease or other

TABLE 2
HL-A 27 IN RHEUMATIC DISEASE PATIENTS*
Presence of HL-A 27

Percentage

Source

119/ 1456

8%

Russell, 1972
Brewerton, 1973
Schlosstein, 1973
White, 1972

10/ 119

8%

Schlosstein, 1973

6/ 66

9%

Schlosstein, 1973

Ankylosing spondylitis

35/ 40
72/ 75

88%
96%

Schlosstein, 1973
Brewerton, 1973

Reiter's syndrome

25 / 33

76%

Brewerton, 1973

Acute anterior uveitis

26/ 50

52%

Brewerton, 1973

6%
14%

White, 1972
Russell, 1972

71 %

Metzger, 1974

Condition
Normal

Rheumatoid arthritis
Gout

Psoriasis
Psoriasis / spondylitis

9/ 156
6/ 44
10/ 14

* A compilation of rheumatic diseases and HL-A 27 shows its strong association with ankylosing spondylitis, Reiter's syndrome, and psoriatic spondylitis.
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to be done in this regard to implicate HL-A 27 as
an etiological factor.

RACIAL ASPECTS OF ANKYLOSING SPONDYLITIS*
1. Random study McGuire VA H: 26 white, 3 black.Toone 1949
2. Combined VA H study, 301 pts. 10% black.Baum 1971
3. HL-A 27 absent in Black Africans.-Dausset
4. HL-A 27 only 4% in Black Americans.
5. HL-A 27 present in 8 of IO Black American spondylitics.
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* The above figures demonstrate the relationship of
HL-A 27 and ankylosing spondylitis on Black Americans.
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rheumatic diseases ( 8 % ) . Therefore, 14 % of our
cases of anterior uveitis had some rheumatological
problem. Ninety-six percent of the cases in our
series with midsegment disease had no apparent diagnosis after workup. Two percent were diagnosed as
spondylitis. Perhaps, a reason for the small number
of diagnoses is that ankylosing spondylitis and sacroiliitis have, in the past, been overlooked.
Dr. Irby: So what can we conclude from this
discussion?
1. There is an 88-95% incidence of HL-A 27
antigen in patients with ankylosing spondylitis and
a 76% incidence in patients with Reiter's disease
against an 8 % incidence in a controlled Caucasian
population.
2. First degree relatives of spondylitics have
20-30 times the risk of developing spondylitis and
50% of these will have HL-A 27.
3. The HL-A 27 antigen may be a useful tool
in diagnosis or prognosis, particularly in early rheumatic disease patients including those with juvenile
rheumatoid arthritis.
4. There is a possibility that HL-A 27 may
predispose a patient to develop Reiter's disease or
ankylosing spondylitis; however, much work needs
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WALTERS D, JAMES DCO: Reiter's disease and HL-A. Lancet
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TABLE4
HEREDITARY ASPECTS OF ANKYLOSING SPONDYLrns*
1. 30X more prevalent among relatives of spondylitic
patients than controls.-Stecher
2. 22.6X more prevalent in relatives of spondylitics than
controls.- De Blecourt
3. W-27 found in 31 / 60 1° relatives.- Brewerton
4. No blood group association.

* The hereditary aspects of ankylosing spondylitis
are clinically apparent as well as genetically significant.
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Juvenile Rheumatoid Arthritis: Early Diagnosis,
Management, and Prognosis***
JOHN J. CALABRO, M.D., F.A.C.P.
Chief of Medicine & Director of Rheumatol'ogy, Worcester City
Hospital; Consultant in Pediatric Rheumatology, New England
Medical Center, Boston, Massachusetts; Professor of Medicine,
University of Massachusetts Medical School, Worcester

Rheumatoid arthritis (RA) is the major chronic
rheumatic disorder of childhood. It affects as many
as 250,000 American children and is slightly more
common in girls than in boys.
Juvenile rheumatoid arthritis (JRA) is arbitrarily defined as RA beginning before the age of
16. It rarely begins before six months of age, and
most cases appear between the ages of one and
three with a second peak at 8-12 years of age.
Despite the inclination to link RA and JRA
as identical diseases, one occurring in adults, the
other in children, there are a number of striking
differences between the two ( 1-5). In a comparative survey (Table 1), high fever and rheumatoid
rash occurred far more frequently in children than
in adults with RA. Another important differenc1.'! is
that chronic iridocyclitis developed in 8 % of patients with JRA. Such ocular involvement is .rare in
adults with RA, if it occurs at all. Of all children
with JRA, the most susceptible group are those with
the mildest form of disease-those whose initial onset is monarticular and those whose course of disease
is oligoarticular (pauciarticular); about one in five
will develop this potentially serious eye inflammation. A monarticular onset, primarily of a kn•ee, was
found more often in JRA than in adult RA. This is
difficult to explain, as is the relative infrequency
among children of subcutaneous nodules. Fewer
children (8 % ) had rheumatoid nodules than adults

* Presented by Dr. Calabro at the 45th Annual
McGuire Lecture Series, November 9, 1973, at the Medical
College of Virginia, Richmond .
**Supported in part by a grant from the Massachusetts
Chapter of the Arthritis Foundation.
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(20%) . They occurred, however, in the same areas
in both groups. Nodules are seen frequently at the
elbow or may be found in any area of pressure or
friction, such as the knuckles or at the back of
the heels. Rheumatoid factor in the serum, as
observed by either a positive sheep cell agglutination or latex fixation test, is present in only 10-25%
of JRA patients, whereas in adults, it is found in
50-85 % . Failure to appreciate the relative infrequency of rheumatoid factor in JRA constitutes one
of the major pitfalls in early diagnosis.
EARLY DIAGNOSIS

Clearly, it is precisely these major differences
that have created much of the difficulty in the early
diagnosis of JRA. The problem would be simpler by
the recognition of three distinct modes of onset.
These are acute febrile (systemic), polyarticular, and
monarticular. The frequency, severity, and character
of initial systemic and articular manifestations help
to differentiate each.
An acute febrile or systemic onset is marked by
systemic manifestations, including high fever, rash,
generalized lymphadenopathy, splenomegaly, and
heart involvement. Joint manifestations are variable;
occasionally only arthralgia is present. In polyarticular onset, defined as the involvement of more than
four joints, the arthritis predominates and is frequently generalized and symmetric, similar to RA
in adults. Systemic manifestations are less prominent
than in an acute febrile onset and fever is low grade.
In a monarticular onset, arthritis is confined to a
single joint, usually a knee ; except for iridocyclitis,
systemic manifestations are either absent or minimal.
MCV QUARTERLY 10(2): 82-90, 1974
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TABLE 1
MAJOR

DIFFERENCES

100 ADULTS

BETWEEN

1()()

CHILDREN

AND

WITH RHEUMATOID ARTHRITIS

CONSECUTIVE REFERRALS TO AN ARTHRITIS CLINIC

Disease Feature
High Fever
Rheumatoid Rash
Chronic Iridocyclitis
Monarticular Onset
Subcutaneous Nodules
Rheumatoid Factor*

* By

Frequency(%)
Children
Adults

20

3

36
8
32

0
6

2

8

20

23
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the latex fixation test, titer of 1: 160 or greater.

Acute Febrile Onset. About 20% of all JRA
patients present with an acute febrile or systemic
onset. Recognition is easy when obvious arthritis is
present in addition to several typical systemic manifestations of the disease (Fig. 1 ) . Sometimes, however, only arthralgia is present and then the differential diagnosis can be difficult. In those without
arthritis, the child's appearance may provide the
first diagnostic clue. These children are irritable,
listless, anorectic, and losing weight. They often wish
to be left alone and assume a position of generalized
flexion. Of the many systemic manifestations, fever
and rash have the greatest diagnostic value. Both
may be associated with g~neralized lymphadenopathy (particularly axillary and epitrochlear nodes),
splenomegaly, hepatomegaly, pericarditis, myocarditis, pneumonitis, and a striking neutrophilic leukocytosis.
Fever. First, it should be remembered that high
fever may precede detectable signs of obvious arthritis by weeks, months, or rarely, by years ( 6).
Rectal temperatures must be taken every four hours
around the clock in order to disclose the characteristic quotidian or double quotidian febrile pattern
(Fig. 2). Typically, there are one or two daily
temperature peaks above 102°F, occasionally even
to hyperpyrexic levels (fever to 105°F) ( 6). Diurnal
ranges are wide, often as much as 8°F or 9 °F, so
that both hyperpyrexia and normal or subnormal
temperatures occur within the same day. The fever
usually, but not always, responds to aspirin provided
large quantities, up to as much as 130 mg/ kg (1
gr/ lb) daily, are given. If the critical daily quantity
of aspirin is then reduced, even by as little as 150
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mg, the fever recurs promptly ( 6, 7). Eventually
the fever pattern may become relapsing or even
periodic ( 6), at which time other typical features
of JRA become manifest, thereby facilitating a correct diagnosis.
Rash. The rheumatoid rash develops in up to
90% of children with an acute febrile onset (8)
(Fig. 1). It consists of macular or slightly maculopapular lesions, usually discrete but sometimes
confluent, that are found on the trunk and extremities and occasionally about the neck and face. Rarely
is the eruption pruritic.
While it may be persistent, more frequently the
rash tends to be fleeting or evanescent, with migratory macules appearing briefly in the late afternoon

Fig. 1-The five-year-old girl above with acute febrile onset
refuses to rotate her head because of cervical pain. Note
typical anxious appean1nce, axillary prominence resulting
from lymphadenopathy, symmetrical swelling of hand and
wrist joints, and macular rash on the chest. (Reprinted by
permission from Med Clin N Amer 25:567, 1968.)
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Fig. 2-The characteristic fever pattern of acute febrile
onset, as shown above in a six-year-old boy, bears considerable diagnostic importance. High fever with its single
and double <lailrpeaks is suppressed only when the daily
aspirin dosage is pushed to 110 mg/kg; patient's weight is
22.7 kg. (Reprinted by permission frqm N Engl I Med
276: 11, 1967.)

or early evening, often in conjunction with fever
spikes. The rash is most florid in areas where the
skin has been rubbed or subjected to mild trauma,
such as the light pressure of clothing. This manifestation is known as the Kohner phenomenon; it
may be useful, diagnostically, when parents report
rash that is not present at the time the child is being
examined. The typical rash may be elicited by making scratch marks on the extremities or along the
lower abdomen. Within several minutes, linear
chains of isolated macules will appear that ofte·n
persist for a day or two (Fig. 3) .
Clearly, in these patients, it is the invariable
combination of fever, rash, arthralgia, and other
systemic features that leads one to an early diagnosis of acute febrile JRA. Otherwise, these patients
are considered to have "fever of unknown origin."
They will be hospitalized repeatedly, undergo exhaustive diagnostic workups, and receive needless
courses of various antibiotics and even exploratory
laparotomy. Differe~tial diagnosjs includes eliminating infection as well as other causes of high fever
accompanied by rash and joint pain.
One of the most important disorders to rule out
is systemic lupus erythematosus (SLE), which is
unusual in a child younger than five years of age.
Occasionally, the early skin lesions of SLE may
resemble the rheumatoid rash, particularly when
localized in the arms and trunk. Eventually, the

rash of SLE takes on its typical butterfly distribution
over the face and the diagnosis becomes apparent.
Also, in SLE, the rash is not evanescent, is not
timed to fever spikes, and does not produce an
isomorphic response. Further, SLE may be confirmed by the presence of oral lesions, renal abnormalities, and LE cells. Finally, the absence of
antinuclear antibodies virtually excludes a diagnosis
of SLE.
Connective tissue disorders other than SLE
must also be excluded. The rashes of HenochSchonlein ( anaphylactoid) purpura, polyarteritis,
and hypersensitivity angiitis are usually purpuric or
ecchymotic. Also, each of these disorders is commonly associated with hypertension and renal manifestations which do not occur in JRA. In the child
with arthritis and purpura, one must also suspect
acute leukemia. Signs that suggest leukemia are
severe anemia, leukopenfa, and destructive lesions
on x-rays of joints, each of which is distinctly
unusual in the initial months of JRA (9).
Polyarticul~r Onset. This mode of onset, with
arthritis of more than four joints, occurs in about
half of all JRA patients. Most children appear ill
and fail to grow. Rash, lymphadenopathy, and
splenomegaly occur less frequently than in acute
febrile 0;nset, and the fever is low grade-peaking
at 101-102°F once or twice daily. Polyarticular
JRA is recognized easily when the pattern of joint
involvement i~ generalized and symmetric and involves the hands (Fig. 4); however, when the
arthritis is c.onfined to large joints, is asymmetric,
or is migratory, it may be confused with other

Fig. 3-Physician has evoked linear macules (Kobner
phenomenon) by lightly scratching the patient's abdomen.
(Reprinted by permission from I Pediat 72: 611, 1968.)
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Fig. 4-Hartds of a ten-year-old girl with polyarticular onset
disclosing symmetrical swelling of proximal interphalangeal,
metacarpophalangeal, and wrist joints. (Reprinted by permission from M ed Clin N Amer 52:567, 1968.)

rheumatic disorders, particularly rheumatic fever
(RF).
The individual macules of RF usually appear
as open rings with distinct outer edges; there are
only a few discrete tnacular rings with pale centers
(Fig. 5) . Typically, the erythema marginatum of
RF extends centrifugally while the proximal skin
returns to normal. It rarely lasts for more than a
week or two, unlike the rash of IRA which persists
for months.
Differential diagnosis is aided by close observation of the fever pattern; quotidian or double quotidian fevers suggest IRA, while remittent or sustained fevers point to RF. Several other features
help to rule out RF. The most important include
onset under follcr years of age, cervical involvement,
a poor mucin clot on synovial fluid analysis, generalized lymphadenopathy, hepatosplenomegaly in
the absence of cardiac failure, and arthritis lasting
for more than 12 weeks.
Arthritis develops in 3 % of all children who
are vaccinated against rubella and involves primarily the knees or wrists. Developing within twoto-eight weeks after vaccination, the arthritis is selflimited, persisting for a few days to several weeks.
The most important laboratory clue is a rising
hemagglutination-inhibition antibody titer.
Another misdiagnosis is childhood dermatomyositis, primarily because the arthritis is so
similar to that of IRA. lnitiaily, loss of muscle
strength is minimal and serum muscle enzyme levels
may be normal while only arthritis predominates.
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Clues to an early diagnosis of dermatomyositis include a violaceous periorbital edema (heliotrope
facies) and the presence of atrophic and scaly
erythema of the skin over extensor surfaces of joints,
particuiady the knees, elbows, and hands.
Monarticular Onset. While the knee is the
most common site of a monarticular onset (Fig.
6), the presentation may sometimes occur in other
joints such as the ankle, elbow, wrist, or even a
finger joint ( 10). Swelling, stiffness, and pain are
usually minimal except when the hip is involved.
Occasionally, painful tendinitis or bursitis, particularly of the heel, may be a presenting symptom.
Symptoms or attention to the problem may be
precipitated by trauma, a deceptive characteristic
and a majo_r pitfall in diagnosis of this mode oJ onset.
It is ironic that the mildest form of IRA, a
moharticular onset, which comprises a third of all
IRA patients, carries with it the serious threat of
blindness from iridocyclitis ( 11) . What makes this
ocular manifestation particularly treacherous is that
it is so often asymptomatic in its evolution, smoldering quietly for weeks or months until failing vision
alone compels attention. It may be the initiai manifestation of IRA or it may occur at any time in the
course of the disease, eveh after the arthritis has
remitted. If undetected and untreated, it may lead
to blindness, primarily from band keratopathy and
cataracts. While iridocylitis may occur in all children with IRA, those with monarticular onset are
by far the most susceptible.
Except for the iridocyclitis, one cannot rely

Fig. 5-In rheumatic fever, most macules appear as open
rings with distinct outer borders and are larger than those
observed in IRA. (Reprinted by permission from I Pediat
72:611, 1968.)
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Fig. 6-Monarticular onset in a three-year-old girl with
painless swelling of the right knee.

on systemic manifestations in this mode of onset.
Lymphadenopathy and splenomegaly occur infrequently, while low-grade quotidian fever and rash
are only occasionally present. Routine laboratory
studies, such as the CBC and ESR, are frequently
normal.
When one joint is involved, the single best
test-if the disease is to be differentiated from acute
infectious arthritis, which may rapidly destroy the
joint-involves arthrocentesis and evaluating the
synovial fluid. The first clues are provided by study
of the gross appearance of the fluid. In JRA, the
fluid will be clear-to-opalescent, in traumatic arthritis it may be clear-to-blood-tinged, while in infectious arthritis it will be cloudy or turbid. Examination of a drop of the fresh, uncentrifuged
fluid under an ordinary microscope may reveal bacteria in infectious arthritis.
Next in order is inspection of the mucin clot.
A few drops of synovial fluid are added to a small
beaker containing about 10 ml of 5% acetic acid.
If the sample is too small to allow this, the acetic
acid can be drawn into the syringe, and even a slight
amount of synovial fluid coating the syringe will
suffice for the test. After allowing a minute for the
clot to form, the container is shaken. A good clot
forms a firm, ropy mass that does not fragment when
shaken. A poor clot quickly flakes and shreds,
clouding the solution. If the etiology of the arthritis is traumatic, the clot will be good; if rheumatoid, it will be good or poor; and if infectious, it
will be poor.
The clinical laboratory is required for further
synovianalysis. In traumatic involvement, the white
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cell count will' be below 5,000, with fewer than 50%
neutrophils; in JRA it will be between 15,000 and
25,000 and the neutrophils will range from 50-90%;
in infectious arthritis, white cells will soar to counts
of 50,000-100,000 and more than 90% will be neutrophils. Of particular interest are the paired determinations of serum and synovial fluid glucose levels;
only in traumatic arthritis will these be about the
same or show a disparity of less than 10 mg% .
In JRA the difference will generally fall between
10-25 mg%, while in arthritis of infectious origin,
it will usually be over 50 mg%
A negative tuberculin skin test usually rules out
active tuberculous arthritis. If it is still necessary to
pursue this possibility, synoviai biopsy will generally show caseating granulomas and giant cells,
while in JRA ohe will see nonspecific synovitis with
hypertrophy, increased vascularity, and round-cell
infiltration.
Laboratory and X-Ray Aids. Low-grade anemia
and an elevated ESR are frequent, except in patients
with a monarticular onset in whom values for hemoglobin, hematocrit, and . the ESR are often normal.
In acute febrile onset, there is a neutrophilic leukocytosis, usually between 20,000 and 30,000 cells,
but sometimes as high as 50,000 cells/mm3 • A
less striking leukocytosis occurs in a polyarticular
onset, while white cell counts are often normal in a
monarticular onset. Leukopenia rarely occurs in
JRA; its presence should lead one to suspect leukemia or SLE.
The latex fixation test is positive in only 1025 % of children with JRA. Elevated titers are found
primarily among children whose disease begins at
12-16 years of age. Antinuclear antibodies (ANA)
are present in 10-30% of patients with JRA. Titers,
however, are much lower than those found in children with SLE. Miller (12) has shown that the
incidence of ANA is highest in girls and in patients
under six years of age. ANA also seems to correlate
with the presence of iridocyclitis ( 2). As for serum
immunoglobulins, persistently elevated levels of IgG,
IgA, and IgM are generally associated with an increased incidence of hip involvement and a poorer
functional status. Serum electrophoresis may reveal
low albumin and elevated ~- and y-globulins. It also
serves to detect underlying hypogammaglobulinemia.
Antistreptolysin-0 (ASO) titers, prolonged and
moderately elevated, occur in about 30% of patients
with JRA. The titers appear to be nonspecific and
are also found in childhood tuberculosis, nephrosis,
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and hepatitis ( 5). They can be inhibited by adding
albumin to the test procedure, in contrast to specific
ASO titers, which indicate recent infection with
Group A ~-hemolytic streptococcus. Intramuscular
monthly injections of benzathine penicillin over a
period of 12 months failed to lower titers of ASO in
six of our patients with JRA, seemingly confirming
the nonspecific nature of these titers ( 5).
Early x-ray findings are also nonspecific and
include soft tissue swelling, early closure of epiphyses,
and periosteal proliferation ( 5). Osseous erosions
are only late findings, and their early presence should
lead one to suspect leukemia or other forms of
malignancy ( 9).
COURSE OF DISEASE

The subsequent course of disease is largely
determined by the mode of onset ( 1) (Table 2).
Three patterns of disease course may evolve: polycyclic acute febrile, polyarthritis, and oligoarthritis
(also known as pauciarticular arthritis).
Ten of our 20 patients with an acute febrile
onset have had recurrent flare-ups of systemic features, primarily high fever and rash, and little or
no arthritis-a disease course designated as polycyclic acute febrile. The number of acute febrile
attacks has varied from one to as many as ten in a
single year. None of these ten patients has ever
developed chronic arthritis. The other ten patients
developed polyarthritis or the simultaneous arthritis
of more than four joints. This occurred either at
the onset of disease or only after months-to-years of
recurrent acute febrile attacks. One girl had periodic
fever that recurred regularly every three months for
as long as nine years (from age 3-12) before she
developed poly arthritis ( 6) .

Of the 32 patients with a monarticular onset,
22 became oligoarthritic, with chronic, often recurrent, arthritis of only one-to-four joints; the ten
remaining children developed polyarthritis.
Children with a polyarticular onset remained
polyarthritic. Altogether then, 68 patients ( 48 with
a polyarticular onset, ten with an acute febrile onset,
and ten with a monarticular onset) eventually developed polyarthritis {Table 2). The course of polyarthritis took two forms, one characterized by
exacerbations and remissions (58 patients), the
other by an unremitting and progressively downhill
course (13 patients)-resulting in marked joint
deformities and an enhanced susceptibility to secondary amyloidosis. Amyloidosis should be suspected
when there is progressive hepatosplenomegaly or
when proteinuria develops that is unrelated to gold
therapy.
MANAGEMENT

The aim of treatment is to provide a setting
that will give the young patient a reasonably normal
childhood. Management must include an active home
program and regular follow-up care, because therapy
may have to be changed at any time during the long
course of the disease ( 13).
From the outset, the physician must recognize
that he can only initiate and supervise therapy. The
actual treatment will be given in the home, and the
results will depend on establishing a working relationship with the parents. Therefore, the physician
must educate and motivate the parents. He must
teach them all about their child's disease-what they
must do, and what they may expect. This is clearly
the best way to reassure the parents and to allay
their anxieties.

TABLE2
THE ONSET, COURSE, AND OUTCOME OF

100

PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS OBSERVED FOR

15

YEARS*

Outcome(%) After 15 Years

Modes of Onset

%

Course of Disease

%

Still Active

Acute Febrile
Polyarticular
Monarticular

20~

48
32

Polycyclic AcFeb
Polyarthritis
Oligoarthritis

10
68
22

28t
7

Classes
III-IV

Itidocyclitis

0

0

13t
0

6:j:

2

* During these 15 years, 88 of-our 100 children were maintained only on aspirin. Only four children have received oral steroids
for more than one year, two because of protracted iridocyclitis; eight are currently on gold therapy.
t Including three deaths, one from postsurgical sepsis, one from secondary amyloidosis, and one of suicide.
i Two children are blind in one eye.
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Drug Therapy. Salicylates. While physical therapy is the most important part of home care, it can
only be made possible by the use of antirheumatic
drugs that reduce joint inflammation and increase
mobility. Whatever the mode of onset, aspirin, in
individualized doses, is the drug of choice. Active
disease can be suppressed in most children by fourto-six daily doses, totaling 90-130 mg/ kg (2/ 3-1
gr/ lb) daily. Acute febrile disease requires the more
frequent and higher doses.
Early signs of chronic salicylate intoxication
can easily be overlooked. Parents must be instructed
to watch for lethargy and episodic hyperpnea, changes
that are especially important in a child who is too
young to complain of tinnitus. When these symptoms
occur, aspirin should be stopped for 24 hours, and
then reinstituted at slightly lower doses.
Adrenocorticosteroids. These drugs are administered in heart failure due to myocarditis as well as
in pericarditis, vasculitis, and protracted iridocyclitis.
For short periods, they may also be given in acute
febrile disease or to patients who either do not
tolerate or who fail to respond to aspirin. Intraarticular injections of steroid may also prove beneficial, especially when one or two joints are so
seriously inflamed that exercise and other rehabilitative efforts are being compromised.
Chrysotherapy. Children with polyarthritis who
respond poorly to aspirin should be given a trial of
gold therapy; however, only physicians experienced
in its use and potentially serious side effects should
prescribe and administer gold. Gold salts are injected intramuscularly at weekly intervals in a dose
of 0.5-1 mg/ kg. Complications are more frequent
during the early months of therapy and in children
less than six years old. Renal and hematopoietic
side effects are potentially fatal, and it is, therefore,
necessary to monitor the patients with weekly blood
and urine tests. These tests must be evaluated before
each injection.
Other Drugs. The antimalarial drugs are not
recommended for routine use in children. Chloroquine is especially dangerous; the accidental ingestion of as little as one gram (four tablets) may cause
rapid cardiorespiratory arrest. Serious toxic effects
to phenylbutazone and oxyphenbutazone include
hepatitis, thrombocytopenia, and agranulocytosis,
which seem to occur more frequently in children
than adults. For this reason, these drugs are currently contraindicated in children 14 years of age
or under. So, too, is indomethacin. The place of
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immunosuppressive or cytotoxic agents has not yet
been evaluated in JRA.
Eye Care. Susceptibility to iridocyclitis is enhanced in all patients with JRA. The recognition
and therapy of iridocyclitis should be entrusted to
an ophthalmologist. In those with minimal arthritis,
the most susceptible group, slit-lamp examinations
are required every three months, even if the arthritis
is in remission. Patients who have had previous
iridocyclitis should be examined on a monthly basis.
All other JRA patients should be examined regularly
by slit lamp at six-month intervals. Ophthalmologic
screening should be routine until patients reach
adulthood, at which time attacks tend to become
acute and routine screening for silent iridocyclitis
is no longer necessary.
Supportive Care. Appropriate rest, splinting,
and exercise are fundamental to the prevention and
:;orrection of deformity. An increase in the hours of
sleep at night and a nap during the day facilitate the
resolution of synovial inflammation. Complete bed
rest must be avoided, however, since this may cause
undue flexion contractures and muscle atrophy.
Bivalved splints, made of plaster of paris or of
plastic, are used to rest inflamed joints or to correct
deformities . Traction, sandbags, or other means of
keeping joints in proper alignment may be used in
place of resting splints. For sustained deformities-a
flexion contracture of a knee, for example-serial
splinting may be useful. New bivalved splints are
applied every one-to-two weeks as the range of
motion improves. Splints may be removed daily to
permit prescribed exercises and then replaced.
A physiatrist or physical therapist must teach
the patient or parents a program of regular daily
exercises that can be performed in the home. Daily
activities, in addition to formal exercise, should be
those that maintain strength and move joints primarily through motions of extension. Games and
sports can help to achieve these goals, but those
which involve sharp impact to the joints, such as
basketball or football, must be avoided. Swimming
is an excellent sport, since it promotes mainly
extension-type movement and has the added advantage of the positive buoyancy of water. Keeping
the child in school also assures that mental activities
are maintained. Provisions must be made, however,
to allow the patient more freedom than other
children.
Surgery. Established deformities can be successfully corrected by a variety of procedures, even in
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the presence of active disease. Early synovectomy,
or the removal of granulation tissue early enough to
prevent erosion of cartilage and bone, however, is an
area of current controversy. The correct timing of
the procedure and the proper selection of patients
are the issues at the moment. Generally, children six
years or younger are poor surgical risks because of
their inability to cooperate fully with important postoperative measures.
PROGNOSIS

Generally, the prognosis for children is quite
favorable ( 1, 2). Of our 100 patients now observed
prospectively for 15 years, 64 are in remission
(Table 2 )-they are not taking any drugs and have
no evidence of active articular or systemic disease.
All 64 patients are in functional classes I and II
and therefore capable of all ordinary activity.
Active disease was present in 36 patients, including the three who died. Of the 36, 28 have had
a course of polyarthritis. Only one of ten patients
with a polycyclic acute febrile course and seven of
22 with oligoarthritis continue to be active, affirming
the benign nature of these two patterns of disease
course.
Only 13 patients are in the unfavorable American Rheumatism Association functional classes III
and IV and are capable of little or no activity. Each
has had a course of unremitting polyarthritis and ten
have had progressive hip involvement. Three of
these patients died, one of staphylococcal bacteremia
following knee synovectomy, one from secondary
amyloidosis, and the third of suicide. Permanent
stunting of growth occurred in seven of these 13
patients, six of whom also had pronounced micrognathia and progressive cervical involvement.
One of our most striking observations is that
chronic iridocyclitis appeared and recurred primarily
in patients with the least amount of joint involvement
(Table 2). Of the eight patients with iridocyclitis,
six had oligoarthritis, two of whom lost vision in one
eye. Iridocyclitis subsequently recurred in three of
these six children and in two when their arthritis
had been in remission for as long as four years.
CONCLUSIONS

Varying degrees of systemic and articular involvement characterize the three modes of onset
observed in JRA. Systemic features, notably high
fever and rash, characterize an acute febrile onset
which may be observed weeks, months, and even

years before objective arthritis develops. In polyarticular onset, the arthritis predominates and is
frequently generalized and symmetric, similar to
adult RA. Monarticular onset, with arthritis confined to a single joint, is the mildest form; it poses,
nevertheless, the major threat of potential blindness
from chronic iridocyclitis.
Treating the patient with JRA is a long-range
collaborative effort, the success of which will largely
depend on early diagnosis along with home care
and parental cooperation. For all modes of onset,
and subsequently during active arthritis, aspirin
continues to be the drug of choice. Management must
include regular follow-up and comprehensive care
to prevent joint deformity and blindness due to
asymptomatic iridocyclitis. The prognosis is generally favorable, as gleaned from our 15-year prospective study of 100 patients, and this allows us to
discard old fears that JRA is inevitably unremitting
and largely intractable to treatment.
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Systemic manifestations of gonococcal disease,
such as arthritis, are often sterile on the usual
culture methods used to grow gonococci. Allergic
mechanisms have been invoked to explain this but
with little evidence to support the concept (1-3).
With the report by Holmes et al. ( 4), that L-forms
of gonococci were isolated from joint fluid of a
patient with gonococcal arthritis, we decided to
investigate the possible role of L-forms in gonococcal
disease.
Biology of L-Forms of Bacteria. Kleineberger in
1935 (5) first described L-form formation in
Streptobacillus moni.liformis organisms. L-forms of
organisms are also known as protoplasts, variants,
or spheroplasts. In protoplast formation, organisms
lose their normal rigid cell walls and are able to
survive, reproduce, and revert to the normal cell
wall possessing parent forms. These features distinguish L-forms of bacteria from mycoplasmas,
which never have rigid cell walls. Media, made
hypertonic with sucrose, sodium chloride, or other
things, are necessary to grow L-forms without lysing
the cells and destroying them. Lacking cell walls,
L-forms do not show up on the usual Gram's stain.
Numerous species of bacteria, including E. coli,
staphylococci, enterococci, and certain fungi are
capable of L-form formation ( 6). This phenomenon
can be induced by the presence in hypertonic media
of certain amino acids, some antibiotics, lysosomal
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enzymes, or the combination of complement and
antibodies.
The question of pathogenicity of L-forms is
far from answered. Work by Gutman et al. (7)
clearly demonstrated that protoplast formation is
a mechanism whereby organisms can persist in the
urinary tract despite antibiotic therapy. Antibiotic
therapy with ampicillin caused Proteus mirabilis
organisms in their patient to revert to L-forms which
are quite resistant to ampicillin. With cessation of
therapy, the organism can revert to the parent form
possessing a cell wall-thus assuring persistence of
the infection.
Seven L-form media, the formulae of which
have previously been published ( 8), were simultaneously inoculated with a recently isolated strain
of Neisseria gonorrheae. In order to increase L-form
colony recovery, one of the four cell wall antibiotics
( ampicillin, benzathine penicillin, methicillin, or potassium penicillin G) was incorporated into the
seven media. This comparison was repeated with
21 strains of gonorrheae and with each of the four
antibiotics to give a total of 588 comparisons. There
was a total of 187 cultures which demonstrate the
presence of L-form cultures; however, three media
accounted for 62% of the positive cultures. These
three high recovery media were used, without antibiotics, in conjunction with chocolate and ThayerMartin media, in two clinical studies designed to
isolate L-forms or coccal forms of gonorrheae.
In the initial clinical study we cultured on high
recovery media material from the urethral exudate
of twelve patients with acute urethritis. None of
these grew L-forms. In the second clinical study we
91
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cultured JOlllt fluid from 17 patients with acute
arthritis. Twelve of these had clinical features suggestive of gonococcal arthritis; again, no L-forms
were grown. Five patients with either gout or osteoarthritis grew no organisms. Thus we were unable to
demonstrate a role for L-forms in the pathogenesis
of gonococcal disease.
That L-forms are present in some patients and
stages of infection cannot be denied on the basis of
Holmes' work; neither can it be denied on the basis
of the work of Orcinnikov and Delektorskij (9)
who have demonstrated, by use of electron microscopy, the presence of wall-less gonococcal cells in
prostatic secretions. The possibility also exists, however, that gonococcal L-forms are transitory-that
is, they are injured cells on the way to death and
do not significantly enter into the pathogenic process.
This possibility is reinforced by the present study
and also by that of Orcinnikov and Delektorskij,
because they were able to demonstrate gonococcal
L-forms using electron microscopy; but in no case
were they able to grow the organism.
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Medical College of Virginia, Health Sciences Division of
Virginia Commonwealth University, Richmond

It is the purpose of this presentation to quickly
review some of the important points of the papers
which were presented at the 45th Annual McGuire
Lecture Series on the subject of immunology and
rheumatic diseases. The first paper was presented
by Dr. Mullinax who gave a background on the
historical aspects of immunology, beginning with
Jenner and cowpox immunology and immunity to
attenuated smallpox demonstrated in milk maids,
continuing through the contributions of Pasteur,
von Pirquet (on serum sickness), Bence Jones,
and Hargraves (with the LE cell in 1948), down
to modern immunology with antibody structure by
Dr. Porter in 1960. Dr. Mullinax also briefly alluded
to light chains and heavy chains, suggesting that
there were two domains in light chains and four
domains in heavy chains. (This subject was later
presented in more detail by Dr. Franklin.) He then
turned to the B cells and T cells, indicating ·that
B cells were producers of humoral or circulating antibodies whereas the T cells dealt more with cellular
immunity and delayed hypersensitivity. He also introduced the five types of immunoglobulins known
at this time.
Dr. Horwitz described the "three R's" of delayed hypersensitivity. The three R's included recognition, response, and reaction, all of which contributed to the afferent as well as the efferent limb
of the inflammatory reaction. He demonstrated
scanning electron microscopic pictures of B lymphocytes showing rough contour in contrast to the T
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lymphocytes which had a smooth contour. He then
mentioned how these reactions were studied through
skin windows and demonstrated the rosette technique with lymphocytes and sheep red cells. The
disorders of recognition were due to absence of T
lymphocytes. The diseases associated with serum inhibition of the lymphocyte function included various
hematologic disorders and solid tumors, SLE, TB,
multiple sclerosis, hepatitis, and leprosy. He also
stated that as far as the immunosuppressant effects
of drugs on delayed hypersensitivity are concerned,
cyclophosphamide had the greatest effect on the B
lymphocytes whereas 6-MP had the greatest effect
on the T lymphocytes.
Dr. Moncure talked about laboratory studies
in the diagnosis of rheumatic diseases, covering the
third component of complement and ANA titers.
He described the various immunofluorescent patterns
which we see in SLE-peripheral, homogenous,
and nucleolar. About one-half of the patients with
nucleolar patterns are found to have systemic sclerosis. He stated that perhaps the ANA test was
more sensitive and less specific than the LE test.
Patients with juvenile rheumatoid arthritis were not
likely to develop positive rheumatoid factor tests .
Dr. Davis discussed immune complex reactions
of systemic lupus erythematosus. He demonstrated
very well the work of Dixon in the original study
with iodinated bovine serum albumin and anti-BSA
antibody formation, with incorporation of complement and deposition of complexes in the skin, joints,
and heart in complex disease. He also mentioned
the fact that rheumatoid factor added to the system
would further precipitate the DNA-anti-DNA in
the system, possibly indicating the role of rheumatoid factor in rheumatoid arthritis.
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Dr. Rothfield's subject was the diagnosis and
treatment of lupus nephritis. She mentioned the
various types of kidney lesions-focal, diffuse, and
membranous-in SLE nephritis and demonstrated
beautifully the immunofluorescent pattern in the
various types. She pointed out that in order to
study the uptake in the immunofluorescent pattern
in patients who have membranous glomerulonephritis, an H & E section present with the immunofluorescent sample is needed. She also stated ·t hat
CNS lupus may have complexes deposited in the
cord. Elaborating further, Dr. Rothfield indicated
that focal glomerulonephritis patients do not die of
renal insufficiency and that hematuria correlated
closely with activity in SLE. Patients with the diffuse lesions are nearly all dead within three years
even with prednisone and they have the worst prognosis. All membranous glomerulonephritis patients
have nephrotic syndrome and in children, particularly, SLE presents a poor prognosis. Dr. Rothfield's general measures for treatment included rest,
avoiding sun lig~t and immunizations, proper
handling of infecti6ns, and avoiding pregnancy. The
treatment for focal nephritis is steroids. Patients
with membranous , nephritis do not do well on
steroids or immunosuppressive drugs such as
Cytoxan® since this is not an inflammatory lesion
and, therefore, would not necessarily respond readily
to them. Diffuse SLE nephritis, of course, is the indication for the use of combined steroid and immunosuppressive therapy. The question is still uncertain as to whether or not this really will prolong
the life of patients with systemic lupus.
Next, Dr. Ziff delivered the first McGuire Lecture entitled, "The Rheumatoid Synovium." He
pointed out that in the rheumatoid synovium there is
a proliferation of the lining layer as well as an infiltration of the deep layer. The two types of cells
which are present are phagocytic and synthetic cells,
the synthetic cells being the fluid producers. He also
mentioned the presence of the IgG rheumatoid factor complexes which are present in the deep layer.
The formation of inclusion bodies with release of
lysosomal enzymes is thought to be one of the
methods of inflammatory reaction. The second half
of the cycle is the activation of complement complexes which cause chemotaxis. The A and B cells
are the cells in the lining layer, whereas the deep
layer contains deposits of IgG and IgM and deposits
of C3 and C4. This IgG site was indicated as the
site at which rheumatoid factor is formed.
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Dr. Owen spoke about synovial fluid. He demonstrated the value of examining a regular wet-prep
and how one can use compensated polarized
microscopy to differentiate between calcium pyrophosphate crystals and gouty crystals. He stated
that rheumatoid arthritis (RA) cells are not diagnostic of rheumatoid disease but can be quite helpful
in diagnosis if present in the synovial fluid. He also
discussed the benefit of determining synovial fluid
complement since when elevated, .i t is an aid in
differentiating Reiter's syndrome from some of the
other nonspecific cases of inflammatory synovitis.
Dr. O'Brien followed with a discussion of some
of the newer nonsteroidal anti-inflammatory drugs
used in the treatment of rheumatoid arthritis. He
began by covering the use of aspirin, gold, and
antimalarials. He pointed out that the problem in
drug evaluation is that in early studies, particularly
with indomethacin, investigators were not geared
up for control studies. We now feel that indomethacin for treatment of rheumatoid arthritis is
not as good as it was at first thought to be. It may
be superior to placebo; perhaps, it is equal to small
doses of phenylbutazone. Dr. O'Brien maintained
that a patient should not be placed on a drug study
unless he was not doing well. He mentioned newer
preparations under investigation, some of which
have been discontinued because of fatal hepatitis.
Some promise was shown for the proprionic acid
derivatives, one of which was fenoprofen calcium
which is less :toxic than aspirin. In a dose of 400
mg per day, it is about as effective as 15 aspirin
tablets daily without the side effects of aspirin. We
have been using this drug on an experimental basis
here for over a year now and find that it is very
effective in the management of some cases of
rheumatoid arthritis. He mentioned some of the
other indole derivatives, all of which have somewhat the same effect as lndocin®.
On the second day of ·the symposium, Dr.
Buckley spoke on the immuncxleficiency diseases.
She discussed agammaglobulinemia associated with
arthritis and reported four patients who had hypogammaglobulinemia. The B cells in these cases are
not able to produce lgG. She also discussed selective lgA deficiency. Some of these patients have
ataxia telangiectasia and chronic, recurring infections, atopic disease, autoimmune disease, and
diarrhea. The lymph node biopsies from these patients may show two different types of findings.
The B cell deficits will show absence of the cortical
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follicles .in the lymph node, whereas the T cell
deficits may show some derangement in the medulla
of the lymph node. She demonstrated some of the
ways of marking B and T cells by using the rosette
method which Dr. Ziff discussed later. The two
types of agammaglobulinemia were contrasted-the
Bruton type and ,the other type in which the plasma
cells did not secrete lgA. Patients with B cell deficits
can live to adulthood but severe T cell deficit patients die within two years. This is the "Swiss" type
of agammaglobulinemia. Bone marrow ·transplantation from a histocompatible sibling may be a lifesaver and about half of those done have been
successful. For treatment of B cell deficiency, she
indicated that the simple use of y-globulin is not
sufficient, that all five classes of immunoglobulin
need to be replaced by plasma infusions in lieu of
injection of y-globulin. Dr. Buckley encouraged the
use of the "buddy system," siblings or friends who
live in the same home who are HAA negative.
Dr. Calabro talked about juvenile rheumatoid
arthritis, early diagnosis, management, and prognosis. He indicated that juvenile rheumatoid arthritis
usually came on before the 16th year of life and
pointed out the differences in the features of juvenile
rheumatoid arthritis and adult rheumatoid arthritis.
The major difference is that adults have rheumatoid
factor present and juveniles, as a rule, do not. Also,
subcutaneous nodules are more common in adults
than in children and the fever, rash, and iritis are
usually not present in adult rheumatoid arthritis but
are present in juveniles. Dr. Calabro described three
modes of onset : the acute febrile or Still's type, the
polyarticular, where four or more joints are involved, and the monarticular, where only one joint
is involved. Patients of the third group are more
likely to develop chronic iridocyclitis and they get
into real difficulty as time goes on. The fever is a
"double" type of fever whereby the temperature at
sometime during the day may go down to below
normal. The fever usually responds very promptly
to aspirin in large doses. The Kobner phenomenon,
similar to an urticaria! type of reaction, is one in
which ,the rash can be brought out with a simple
stroke on the skin. Although quite helpful, this is
not specific for the rash of juvenile rheumatoid
arthritis in that other types of rashes may behave
similarly. The laboratory aids here are the presence
of anemia, elevated ESR and lymphocytosis. These
children frequently have positive ANA titer, may
have positive ASO titer, and the x-ray will frequently
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show periostitis. In Dr. Calabro's 15-year follow-up,
many of the monarticular patients went on to develop polyarticular states and the same was true for
patients with the oligoarticular type. Treatment consisted of aspirin, gold salts, and steroids, with
steroids particularly advisable in the acute febrile
Still's patient where there was pericardia! or eye
involvement.
Dr. Baum discussed ankylosing spondylitis which
he said was not a variant of rheumatoid arthritis.
He stated criteria for diagnosis of ankylosing spondylitis and demonstrated certain feaures in the examination of a patient with ankylosing spondylitis.
A very interesting x-ray finding, the syndesmophyte,
was discussed-vertical syndesmophytes in spondylitis versus horizontal osteophytes in osteoarthritis.
The various associated complications-aortitis, iritis,
heart block, amyloidosis, subluxation, and pulmonary fibrosis-were discussed. The variants of
ankylosing spondylitis-psoriatic, chronic ulcerative
colitis, Whipple's, and Reiter's spondylitis-were
discussed. The work that has been done, particularly
by Dr. Schlosstein and Dr. Terasaki at Los Angeles
on the transplant antigen W-27 locus, was summarized. Eighty-eight percent of patients with
ankylosing spondylitis demonstrated this antigen as
opposed to :an 8 % incidence in a random population. This certainly points to some genetic aspect in
ankylosing spondylitis. It may also have something
to do with the prognostic significance, particularly in
children, if a patient possesses a W-27 antigen locus.
Dr. Franklin, "Mr. Immunoglobulin," talked
about the G, A, M, D, and E myelomas and described the structure of the immunoglobulin molecule
with the Fab fraction or the antigen binding site and
the constant fraction (Fe) of the immunoglobulin.
He listed the various H-chains and L-chains of IgG,
A, M, D, and E and talked about the I-chain. By
the time a diagnosis of multiple myeloma is made,
the chances are that the patient has had the disease
some 15 years prior to the time that bone lesions
appear. The bone pain is usually the factor which
brings the patient to the doctor. The other disorders,
macroglobulinemia, H-chain disease, and the benign
monoclonal gammopathy were discussed. Benign
monoclonal gammopathy is present in about 3%
of patients over 60 years of age. There are about
35 cases of yH-chain, about 50 cases of aH-chain,
and only 7 cases of µH-chain disease reported. These
are very rare, but they have certain characteristics of
yH-chain myeloma and may simulate lymphoma.
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Palatal and uvula swelling are ·two things which
sometimes aid in making the diagnosis. Rarely do
these patients have bone lesions and recurrent infection is usually the reason for seeking medical attention. These patients have a characteristic electrophoretic pattern. Patients with aH-chain disease
usually have malignant lymphoma of the intestine
and malabsorption. The aH-chain is produced in
the plasma cells lining the intestine and may or may
not be malignant. Of seven elderly patients with
µ-chain disease, all had chronic lymphocytic leukemia. Lymphadenopathy is usually absent and these
patients have hepatosplenomegaly and a high incidence of Bence Jones protein and K-light chains in
the urine. The finding that is very helpful in diagnosis of µ-chain is the presence of a large vacuolated
plasma cell which can be found in the bone marrow.
The bad effects caused by these proteins are
the hyperviscosity syndrome, cryoglobulinemia and
Bence Jones protein, the latter of which damages
the kidney. They have bleeding and clotting disorders, infections, hemolytic anemias, and amyloidosis. Dr. Glenner and his group at NIH now
have indicated that light chain fragments are present
in amyloidosis.
Dr. Waller discussed the serum agglutinators
and indicated that rheumatoid factors were IgM,
whereas the serum agglutinators were antiglobulin
antibodies or IgG which are a normal constituent of
serum. These are closely associated with suppurative
infection, particularly gram-positive organisms. The
hidden sites on the Fab fragment are responsible
for the formation of the serum agglutinators after
papain or pepsin digestion. There are about 14.9%
positive serum agglutinators in a hospital population
as opposed to 0.5% in our arthritis clinic. Large
abscesses usually have positive tests; subacute bacterial endocarditis may have positive tests for serum
agglutinators.
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Dr. Ziff presented the second McGuire Lecture
on "Viruses and the Connective Tissue Diseases."
Again he stated that T cell lymphoblasts in the presence of antigen can convert B cells into plasma cells
to produce serum antibody and that virus infections
would diminish T cell formation. Dr. Ziff discussed
further the concept of T cell helper and T cell suppressor substances in which he indicated that viruses
might be an enhancing mechanism to stimulate the
B cells ·t o produce autoantibody.
Dr. Bisno spoke on the subject of acute rheumatic fever and glomerulonephritis with streptococcal antigen. He did mention the fact that ASO is
frequently elevated in throat infections and not
necessarily elevated in pyoderma. The sequelae of
the throat infections are more likely to produce
acute rheumatic fever than acute glomerulonephritis,
whereas the sequelae of the skin infections are more
likely to produce acute glomerulonephritis. Dr. Bisno
briefly discussed the streptozon test, on which he
and his associates are now working, which may be
very helpful in the diagnosis of streptococcal infection and sequelae.
Dr. Blaylock's lecture included a discussion of
urticaria, hives, eczematous dermatitis and rheumatoid lesions. IgE is the immunoglobulin which is
present in patients with urticaria, hay fever, asthma,
and penicillin allergy. He noted ·t hat pemphigus
vulgaris has 7S yG which is usually laid down between the cells and around the keratinocytes. Gamma
G globulins will vary in pemphigus vulgaris, whereas
in bullous pemphigus the serum globulins usually
stay the same. IgG is usually deposited on the basement membrane similar to that in SLE. Dermatitis
herpetiformis produces IgA on the basement membrane.
Dr. Cooke discussed methods of early diagnosis
of gonococcal arthritis and the absolute necessity of
instituting prompt treatment.
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how big a dose will now
bring relie£if it is a narcotic?
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"Tolerance is an ever-present hazard to continued
use of narcotics .... The very f irst dose diminishes the
effects of su bsequent doses." 1 And , as increasing
amounts of narcotics are required to control pain, distressing adverse effects- lethargy, hypotension, constipation , etc.-can need lessly debilitate the pat ient.
1.Sadove, M. S.: A look at narcotic and non-narcot ic analgesics, Postgrad.
Med. 49:102, June 1971.

how big a dose will now
bring relief if it is Talwin?
Chances are, the same 50 mg. Talwin Tablet you
prescribe originally wil l continue to provi de good pain
relief. Ta lwin can be compared to codeine in analgesic efficacy: one 50 mg. tablet appears equ ivalent
in ana lgesic effect to 60 mg. (1 gr.) of codeine. However, pat ients receiving Ta lwi n Tablets f or prolonged
periods face fewer of t he consequences you've come
to expect with narcotics. There should be fewer
"adverse effects" on her way of life.
Tolerance rare: Tolera nce to the analgesic effect of
Ta lwin Tablets is rare.
Dependence rare: During three years of wide clinical use, there
have been a few reports of dependence and of withdrawal symptoms with orally administered Ta/win. Patients wi th a history
of drug dependence should be under close supervision while
receiving Ta/win orally.
In prescribing Ta/win for chronic use, the physician should
take precautions to avoid increases in dose by the patient and
to prevent the use of the drug in anticipation of pain rather
than for the relief of pain.*

Generally well tolerated by most patients*: Infrequently causes
decrease in blood pressure or tachycardia; rarely causes respiratory depression or urinary retention; seldom causes diarrhea
or constipation. Acute, t ransient CNS effects, described in
product information on fo llowing page, have occurred in rare
instances fo llowing the use of Talwi n Tablets. If dizziness,
lightheadedness, nausea or vomit ing are encountered, t hese
effects may decrease or disappear after the f irst few doses.
•see important product inform ation on next page for adverse reaction s, patient
selection, prescribing and precautionary recommendat ions.
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howbig adosewill now
bringr liefifitisanar otie?
"Tolerance is an ever-present hazard to continued
use of narcotics .... The very first dose dimin ishes the
effects of subsequent doses." 1 And, as increasing
amounts of narcotics are required to control pain, distressing adverse effects-lethargy, hypotension, constipation, etc.-can needlessly debilitate the patient.
1.Sadove, M . S.: A look at narcotic and non-narcotic analgesics, Postgrad.
Med. 49:102, June 1971.

how big a dose will now
bring relief if it is Talwin?
Chances are, the same 50 mg. Talwin Tablet you
prescribe originally will continue to provide good pain
relief. Talwin can be compared to codeine in analgesic efficacy: one 50 mg. tablet appears equivalent
in analgesic effect to 60 mg. (1 gr.) of codeine. However, patients receiving Talwin Tablets for prolonged
periods face fewer of the consequences you've come
to expect with narcotics. There should be fewer
"adverse effects" on her way of life.
Tolerance rare: Tolerance to the analgesic effect of
TalwinTablets is rare.
Dependence rare: During three years of wide clinical use, there
have been a few reports of dependence and of withdrawal symptoms with orally administered Ta/win. Patients with a history
of drug dependence should be under close supervision while
receiving Ta/win orally.
In prescribing Ta/win for chronic use, the physician should
take precautions to avoid increases in dose by the patient and
to prevent the use of the drug in anticipation of pain rather
than for the relief of pain.*
Generally well tolerated by most patients*: Infrequently causes
decrease in blood pressure or tachycardia ; rarely causes respiratory depression or urinary retention; seldom causes diarrhea
or constipation. Acute, transient CNS effects, described in
product informat ion on fol lowing page, have occurred in rare
instances fo llowing t he use of Talwin Tablets. If dizziness,
lightheadedness, nausea or vomiting are encountered, these
effects may decrease or disappear after the first few doses.
•see important product information on next page for adverse reactions, patient
selection, prescribing and precautionary recommendation s.
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in chronic
pain of
moderate to
severe
intensity
Talwin® Tablets brand of pentazocine (as hydrochloride)
Analgesic for Oral Use
Indication: For the relief of moderate to severe pain.
Contraindication: Talwin shou ld not be administered to patients

who are hypersensitive to it.
Warnings: Drug Dependence . There have been instances of psychological and physical dependence on parenteral Ta/win in patients with a history of drug abuse and, rarely, in patients without
such a history. Abrupt discontinuance following the extended use
of parenteral Ta/win has resulted in withdrawal symptoms. There
have been a few reports of dependence and of withdrawal symptoms with orally administered Ta/win. Patients with a history of
drug dependence should be under close supervision while receiv ing Ta/win orally .
In prescribing Ta/win for chronic use, the physician should take
precautions to avoid increases in dose by the patient and to prevent the use of the drug in anticipation of pain rather than for the
relief of pain.
Head Injury and Increased lntracranial Pressure. The respiratory
depressant effects of Talwin and its potential for elevating cerebrospina l fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a preexisting
increase in intracranial pressure . Furthermore, Talwin can produce effects which may obscure the c linical course of patients
with head injuries . In such patients, Talwin must be used with
extreme caution and only if its use is deemed essential.
Usage in Pregnancy. Safe use of Talwin during pregnancy (other
than labor) has not been established . Animal reproduction studies
have not demonstrated teratogenic or embryotoxic effects . However, Talwin should be administered to pregnant patients (other
than labor) only when, in the judgment of the physician , the potential benefits outweigh the possible hazards. Patients receiving
Talwin during labor have experienced no adverse effects other
than those that occur with common ly used analgesics. Talwin
should be used with caution in women delivering premature
infants.
Acute CNS Manifestations . Patients receiving therapeutic doses
of Talwin have experienced, in rare instances, hallucinations (usually visual), disorientation, and confusion wh ich have cleared
spontaneously within a period of hours. The mechanism of this
reaction is not known . Such patients should be very closely observed and vital signs checked. If the drug is reinstituted it should
be done with caution since the acute CNS manifestations may recur.
Usage in Children. Because clinical experience in children under
12 years of age is limited, administration of Talwin in this age
group is not recommended.
Ambulatory Patients. Since sedation, dizziness , and occasional
euphoria have been noted , ambulatory patients should be warned
not to operate machinery, drive cars, or unnecessarily expose
themselves to hazards.
Precautions: Certain Respiratory Conditions . Although respiratory
depression has rarely been reported after ora l administration of
Talwin, the drug should be administered with caution to patients
with respiratory depress ion from any cause, severely limited respiratory reserve, severe bronchial asthma and other obstructive
respiratory conditions, or cyanosis.
Impaired Renal or Hepatic Function. Decreased metabolism of the
drug by the liver in extensive liver disease may predispose to
accentuation of side effects . Although laboratory tests have not
indicated that Talwin causes or increases renal or hepatic impairment, the drug should be administered with caution to patients
with such impairment.
Myocardial Infarction. As with all drugs, Talwin should be used
with caution in patients with myocardial infarction who have nausea or vomiting.
Biliary Surgery. Until further experience is gained with the effects

of Talwin on the sphincter of Oddi, the drug should be used with
caution in patients about to undergo surgery of the biliary tract.
Patients ~eceiving t:-Jarcotir:s . Talwin i? a mild narcotic antagonist.
Some i)at1ents previously given narcotics, including methadone for
th.e dally treatment of narcotic dependence, have experienced
withdrawal symptoms after receiving Talwin .
CNS Effect. Caution should be used when Talwin is administered
to patients prone to seizures; seizures have occurred in a few such
patients in association with the use of Talwin although no cause
and effect relationship has been established .
Adverse Reactions: Reactions reported after oral administration of
Talwi~ ii:clude gastrointestinal: nausea, vomiting; infrequently
const1pat1on; and rarely abdominal distress anorexia diarrhea.
CNS eftects: dizziness, lightheadedness, sedation, euphoria, headache; 1~frequentl~ weakness, d_istur~e~ dreams, insomnia, syncope, visual blurring and focusing d1ff1culty hallucinations (see
Ac.ute .CNS Ma.nifestatior:s 1:1nder WARNINGS'); and rarely tremor,
1mta~1l1ty , excitement, tinnitus. Autonomic: sweating· infrequently
flu~h1n~; and rarely chills. Allergic: infrequently rash; and rarely
urt1cari'!, edema of the face. Cardi<;JVascu/ar: infrequently decrease in blood pressure, tachycardia. Hematologic: rarely depressi~n of white blood cells (espe~ially granulocytes), usually
rev.ers1ble and usually associated with diseases or other drugs
which ar.e. known to cause such changes, moderate transient
eos1noph1l1a. Other: rarely respiratory depression urinary retention, toxic epidermal necrolysis.
'
Dosage and Administration: Adults. The usual initial adult dose is
1 tablet (50 mg.) every three or four hours. This may be increased
to 2 tablets ( 100 mg.) when needed . Total daily dosage should not
exceed 600 mg.
When antiinflammatory or antipyretic effects are desired in addition to analgesia, aspirin can be administered concomitantly with
Talwin.
Children Under 12 Years of Age. Since clinical experience in chil~ren. under 12 Y.ears of age is limited , admin istration of Talwin
1n this age group 1s not recommended .
Dura.tion of Therapy. Patients wit.h chronic pain who have received
Talwin orally for prolonged periods have not experienced withqrawal symptoms even when administration was abruptly discontinued (see WARNINGS) . No tolerance to the analgesic effect has
been observe.d . Laboratory tests of blood and urine and of liver aoo
kidney function have revealed no significant abnormalities after
prolonged administration of Talwin .
Overdosage: Manifestations . Clinical experience with Talwin overdosage has been insufficient to define the signs of this condition.
Treatment. Oxygen, intravenous fluids, vasopressors, and other
supportive measurE!s ?hould be employed as indicated . Ass isted
or controlled ventilation should also be considered. Although
nalorph1ne and levallorphan are not effective antidotes for respiratory . depression due to overdosage or unusual sensitivity to
Talw1n, P!Jren.teral na.l~xone (Narcan®, available through Endo
Laboratories) 1s a spec1f1c and effective antagonist.
Talwin is not subject to narcotic controls.
How Supplied: Tablets, peach color, scored. Each tablet contains
Talwin (brand of pentazocine ) as hydrochloride equivalent to
50 mg. base . Bottles of 100.
Winthrop Laboratories, New York, N.Y. 10016 (m~.n7li]
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A service to medical education from A. H. Robins:
Excerpted from Volume 2

oflh'G.I.

Senes

on physical examination
of the abdomen:

Normally palpable organs:
the edge of the liver descending ,
on inspiration, below the costal
margin (A); the lower pole of the
right kidney (BJ; the abdominal
aorta (CJ; the descending colon
and the sigmoid (DJ; the ascending colon CE); and occasionally
the bladder (though rising of
this organ beyond the pubis
does not necessarily indicate
disease)
Impossible to outline, unless
diseased, distended or enlarged:
the gallbladder, pancreas,
stomach, small intestine, transverse colon and spleen .

I:I
~

G.l

The A . H Robins G I. Series consists of six booklets. designed to provide a quick, yet comprehen- I · 1 '
sive review of basic procedures and practices in
G.I. medicine - with particular emphasis on the
physical examination as performed in the office or
::·
at bedside If you have teaching respons1bilit1es.
'·-.... ""'
limited quantities are available: Part 1 - Inspection.
~.:..
Part 2 - Palpation , Part 3 - Percussion. Part 4 - Auscultation, Part 5Abdominal Pain and Part 6 - Different1al D iagnosis of Abdominal
Disorders. Write to: The Medical Department. A. H Robins Company,
1407 Cummings Drive. Richmond . Virginia 23220.
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GI m ed icine - wit h particu lar emp h asis on the
physical examinal1on as perfo rm ed 1n th e office or
at bedsid e If you have teaching respons1b1l1t1es .
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Normally palpable organs:
the edge of the liver descending,
on inspiration, below the costal
margin (A); the lower pole of the
right kidney (B); the abdominal
aorta (C); the descend ing colon
and the sigmoid (D); th e ascending colon (E); and occasionally
the bladder (though rising of
this organ beyond th e pubis
does not necessari ly indicate
disease).
Impossible to outline, unless
diseased , distended or enlarged:
the gallbladder, pan creas,
stom ach, small intestine, transve rse colon and spleen.

each tablet,
capsule or 5 cc .
each
teaspoonful
Don natal
of elixir
No 2
(23% alcohol)
O 1037 mg .
0.1037 mg.
'1yoscyam1ne sulfate
0.0194 mg
atropine sulfate
00194mg .
0.0065 mg
'1yoscine hydrobrom1de
00065mg.
(114 gr.) 16.2 mg (Y.1gr.)32.4 mg.
phenobarbital
warning may be habit forming)

each
Extentab
03111 mg .
0.0582 mg
0.0195mg.
CY. gr.) 48.6 mg .

•

Brief summary. Adverse Reactions: Blurring of vision. dry mouth ,
difficult urination , and flushing or dryness of the skin may occur
on higher dosage levels, rarely on usual dosage. Contraindications : Glaucoma; renal or hepatic disease ; obstructive uropathy
(for example, bladder neck obstruction due to prostat1c hypertrophy); or hypersens1tiv1ty to any of the ingredients.

A·H·ROBI NS

A H Robins Company. Richmond. V1rg1nia 23220

•
each tablet.
capsule or 5 cc.
teaspoonful
each
each
of elixir
Don natal
Extentab
(23% alcohol)
No 2
hyoscyam1ne sulfate
O 1037 mg.
0.3111 mg
0.1037mg
atropine sulfate
0 .0194 mg
0.0582 mg
00194mg.
hyoscine hydrobrom1de
0 .0065 mg
0.0195mg.
00065mg.
phenobarbital
(V, gr.) 16.2 mg (Y.! gr.) 32.4 mg. (%gr.) 48.6 mg.
(warning may be habit forming)

•

Brief summary. Adverse Reactions: Blurring of vision, dry mouth,
difficult urination. and flushing or dryness of the skin may occur
on higher dosage levels, rarely on usual dosage. Contraindications: Glaucoma; renal or hepatic disease; obstructive uropathy
(for example, bladder neck obstruction due to prostatic hypertrophy): or hypersensitivity to any of the ingredients.

A·H·R_O BINS

A H Robins Company. Richmond. Virginia 23220

Before prescribing, please consult
complete product information, a sum·
mary of which follows:
Indications: Tension and anxiety

states, somatic complaints which are
concomitants of emotional factors; psychoneurotic states manifested by tension,
anxiety, apprehension, fatigue, depressive symptoms or agitation ; symptomatic
relief of aci.Jte agitation, tremor, delirium
tremens and hallucinosis due to acute
alcohol withdrawal ; adjunctively in skeletal muscle spasm due to reflex spasm to
local pathology, spasticity caused by
upper motor neuron disorders, athetosis,
stiff-man syndrome, convulsive disorders
(not for sole therapy).
Contraindicated: Known hypersensitivity to the drug. Children under 6
months of age. Acute narrow angle glaucoma; may be used in patients with open
angle glaucoma who are receiving appropriate therapy.
Warnings: Not of value in psychotic
patients. Caution against hazardous
occupations requiring complete mental
alertness. When used adjunctively in convulsive disorders, possibility of increase
in frequency and/ or severity of grand mal
seizures may require increased dosage of
standard anticonvulsant medication;
abrupt withdrawal may be associated
with temporary increase in frequency
and/ or severity of seizures. Advise
against simultaneous ingestion of alcohol
and other CNS depressants. Withdrawal
symptoms (similar to those with barbiturates and alcohol) have occurred following abrupt discontinuance (convulsions,
tremor, abdominal and muscle cramps,
vomiting and sweating) . Keep addictionprone individuals under careful surveil·.
.
lance because of their predisposition to ~(,,....,'°""',......,.,./
habituation and dependence. In preg\ .
"}I
nancy, lactation or women of childbearing
· _,
age, weigh potential benefit against
possible hazard.
Precautions: If combined with other
psychotropics or anticonvulsants, consider carefully pharmacology of agents
employed; drugs such as phenothiazines,
narcotics, barbiturates, MAO inhibitors
and other antidepressants may potentiate
its action. Usual precautions indicated in
patients severely depressed, or with latent
depression, or with suicidal tendencies.
Observe usual precautions in impaired
renal or hepatic function. Limit dosage to
smallest effective amount in elderly and
debilitated to preclude ataxia or oversedation.
Side Effects: Drowsiness, confusion,
diplopia, hypotension, changes in libido,
nausea, fatigue, depression, dysarthria,
jaundice, skin rash, ataxia, constipation,
headache, incontinence, changes in salivation, slurred speech, tremor, vertigo,
urinary retention, blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations,
increased musc le spasticity, insomnia,
rage, sleep disturbances, stimulation
have been reported ; should these occur,
discontinue drug. Isolated reports of neutropenia, jaundice; periodic blood counts
and liver function tests advisable during
long-term therapy.

Ifthere's good reason
to prescribe
for psychic tension...

When, in spite of counseling,
the patient's pattern ofoverreaction to stress
affects his ability to function

Dependable response
1s a good reason
to considerValium

Roche Laboratories
Division of Hoffmann- La Roche Inc.
Nutley. N.J. 07110

(diazepam)
2-mg,5-mg,
10-mg tablets

